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ABSTRACT
Christiansen, Erin Lee. Improving healthcare for adult patients with dual diagnoses of chronic
pain and opioid use disorder. Unpublished Doctor of Nursing Practice scholarly project,
University of Northern Colorado, 2022.

Up to 50 million Americans experience chronic pain. Of those who are prescribed
opioids, 21% to 29% misuse their prescriptions and 8% to 12% will develop an opioid use
disorder. In Colorado alone, the opioid analgesic death rate rose substantially from 102 deaths in
2018 to 540 deaths in 2020. In 2017, the U.S. government declared the sudden rise in
prescription opioid overdose-related deaths a nationwide public health emergency. Chronic pain
patients who are treated with opioid therapies are at risk for opioid dependency and/or abuse,
heroin dependency and/or abuse, overdose, and death from long-term opioid use. Patients
diagnosed with chronic pain and substance use disorder, opioid use disorder, or both are in need
of individualized, holistic, multidisciplinary treatment plan approaches. The purpose of this
Doctor of Nursing Practice scholarly project was to develop a holistic, multidisciplinary clinical
pathway to improve pain outcomes in adult patients who have dual diagnoses of chronic pain and
opioid use disorder. The clinical pathway was designed to benefit patients treated in a private
Midwestern interventional pain management clinic and in similar care environments. Following
the Stetler (2001) model, the pathway was created utilizing evidence found in current literature
and validated through surveying a panel of experts. A panel of chronic pain experts completed
the survey providing data regarding the accuracy, feasibility, potential for provider utilization,
and validity of the proposed clinical pathway.
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CHAPTER I
INTRODUCTION
The opioid crisis has turned into a global pandemic. Adults (age 18 years of age and
older) who are being treated for chronic non-cancer pain with opioids are at an increased risk for
developing an opioid use disorder. According to the National Institute on Drug Abuse (2021), up
to 29% of patients who utilize opioids for the treatment of chronic pain misuse them and between
8% and 12% develop an opioid use disorder. The consequences of the opioid pandemic are
evident in both the increase in overdose death rates and financial losses. In 2015, the estimated
cost of the opioid epidemic in the United States was $504 billion (Substance Abuse and Mental
Health Services Administration, 2021). Alarmingly, drug-related deaths tripled between the
years 1999 to 2015 while deaths related to heroin and illicit synthetic fentanyl continue to rise
(Manchikanti et al., 2017). Demont et al. (2022) reported in Colorado alone over the last 10
years, there have been 10,334 drug overdose deaths with 1,477 of those deaths occurring in
2020. Overdose deaths related to opioid analgesics (including all-natural, semisynthetic,
methadone, and fully synthetic opioids) increased substantially from 102 deaths in 2018 to 540
deaths in 2020 (Demont et al., 2022).
Yet up to 50 million Americans experience chronic pain, many of whom require
medication management including the safe use of opioids as well as conservative and integrated
pain management therapies (Dahlhamer et al., 2018; Kaye, Jones, Kaye, Ripoll, Galan et al.,
2017; Kaye, Jones, Kaye, Ripoll, Jones et al., 2017; Manchikanti et al., 2017). Many physicians
and advanced practice providers struggle with maintaining safe opioid prescribing for patients
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with chronic non-cancer pain while also preventing and treating opioid use disorder. Chronic
pain treatment standards vary widely but are generally congruent with the Centers for Disease
Control and Prevention (CDC, 2021), the American Society of Regional Anesthesia and Pain
Medicine, the American Society of Anesthesiologists, the American Society of Interventional
Pain Physicians (AISPP; Manchikanti et al., 2017), and the American Academy of Pain
Medicine guidelines. The evidence suggested a multidisciplinary approach to treating those with
chronic pain and opioid use disorder was the gold standard of care but when treating this
population, most integrated pain management clinical treatment plans are provider-specific. For
patients who have been diagnosed with opioid use disorder, special treatment considerations
must be taken into account in the outpatient setting (Kaye, Jones, Kaye, Ripoll, Galan et al.,
2017; Kaye, Jones, Kaye, Ripoll, Jones et al., 2017; Marshall et al., 2019). Many providers
working in pain management clinics lack clear algorithms and/or pathways about how to treat
patients with dual diagnoses of chronic non-cancer pain and opioid use disorder; this practice
deficit was the focus of this Doctor of Nursing Practice (DNP) scholarly project.
Background
For decades, advertising propaganda misled medical providers and the public boasting
about the health and nonaddictive benefits of opioids (Scher et al., 2018). Subsequently,
healthcare providers prescribed opioids to their patients believing they were safe. We now know
there was a direct correlation between the number of opioid prescriptions and opioid use disorder
rates (Medina et al., 2019). Opioid prescribing has contributed to the current opioid pandemic
situation. Illicit opioids found on the streets are primarily opioids prescribed to the elderly,
patients with chronic pain, those who “doctor shop,” and pill brokers or dealers (Kaye, Jones,
Kaye, Ripoll, Galan et al., 2017).
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A recent Gallup poll reported nearly one-third of Americans struggled with drug
addiction in their families (Macy & Pelletier, 2021). In the last 20 years, there has been an
average of 115 American deaths every day from an opioid overdose. More than two million
people are currently living with an opioid use disorder diagnosis (American Bar Association,
2021). In 2015, the American life expectancy dropped for the first time since World War I with
the main contributing factor being opioid overdoses (Macy & Pelletier, 2021). Thus, former
President Trump and the Department of Health and Human Services declared the opioid crisis a
nationwide public health emergency in 2017 (Marshall et al., 2019).
Current Opioid Prescribing and Chronic Pain
Treatment Practices
In recent years, federal and state legislation and judicial judgments have attempted to
closely control opioid prescribing and the management of chronic non-cancer pain. At the federal
level, the CDC (2021) created the 2012 Guidelines for Prescribing Opioids for Chronic Pain,
and the AISPP (Manchikanti et al., 2017) guidelines were published in 2017 (Kaye, Jones, Kaye,
Ripoll, Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al., 2017). The CDC guidelines
were last updated in 2016 and are currently under review.
In 2018, the Colorado Senate and House of Representatives adopted Senate Bill 18-022
Clinical Practice for Opioid Prescribing (Colorado General Assembly, 2022). The act placed
restrictions on the quantity of opioids a healthcare practitioner could prescribe for an initial
seven-day prescription. Healthcare practitioners were required to report their specialty to the
prescription drug monitoring program and query the prescription drug monitoring program prior
to subsequent opioid prescriptions (Colorado General Assembly, 2022).
Despite these federal, state, and CDC (2021) initiatives, chronic pain management, and
opioid prescribing guidelines are often vague and allow a significant amount of interpretation for
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the provider. In particular, treatment recommendations for chronic pain in combination with
opioid use disorder remain unclear. Managing chronic non-cancer pain in the presence of opioid
use disorder adds another layer of complexity for clinicians. Opioid use disorder is a subset of
substance abuse disorder (UpToDate, 2022). While this DNP scholarly project focused primarily
on opioid use disorder, some aspects might be appropriate for substance use disorder and other
subsets of this disease.
Diagnosis of Substance Use Disorder
Substance use disorder is diagnosed according to criteria outlined in the fifth edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; Dugosh & Cacciola, 2022).
The DSM-5 is a manual clinicians and researchers might use to define and classify mental health
disorders. According to Dugosh and Cacciola (2022), the diagnostic criteria for substance use
disorder is a problematic pattern of use leading to significant impairment or distress manifested
by two or more of the following within a 12-month period:
•

A substance often taken in larger amounts or over a longer period than was
intended.

•

A persistent desire or unsuccessful efforts to cut down or control use of a
substance.

•

A great deal of time is spent in activities necessary to obtain, use, or recover from
a substance’s effects.

•

A craving or strong desire or urge to use a substance.

•

Recurrent use of a substance resulting in a failure to fulfill major role obligations
at work, school, or home.
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•

Continued use of a substance despite having persistent or recurrent social or
interpersonal problems caused or exacerbated by its effects.

•

Important social, occupational, or recreational activities are given up or reduced
because of use of a substance.

•

Recurrent use of a substance in situations in which it is physically hazardous.

•

Continued use of a substance despite knowledge of having a persistent or
recurrent physical or psychological problem that is likely to have been caused or
exacerbated by the substance.

•

Tolerance.

•

Withdrawal.

Dugosh and Cacciola (2022) described the severity of a substance use disorder at the time
of diagnosis could be specified as a subtype based on the number of DSM-5 criteria present:
•

Mild - Two to three criteria present.

•

Moderate – Four to five criteria present.

•

Severe – Six or more criteria present.

Diagnosis of Opioid Use Disorder
Similar to substance use disorder, opioid use disorder is diagnosed according to criteria
outlined in the DSM-5 (Strain, 2022). Strain (2022) reported the diagnostic criteria for opioid use
disorder as a problematic pattern of use leading to significant impairment or distress manifested
by at least two of the following within a 12-month period:
•

Opioids are often taken in larger amounts or over a longer period than was
intended.

•

Persistent desire or unsuccessful efforts to cut down or control opioid use.
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•

A great deal of time is spent in activities necessary to obtain, use, or recover from
an opioid’s effects.

•

Craving or urge to use opioids present.

•

There is a failure to fulfill major role obligations at work, school, or home related
to the recurrent use of an opioid.

•

Continued use of an opioid despite persistent or recurrent social or interpersonal
problems caused or exacerbated by it’s effects.

•

Important social, occupational, or recreational activities are given up or reduced
because of opioid use.

•

Recurrent opioid use in situations despite physical hazards.

•

Continued opioid use despite knowledge of having a persistent or recurrent
physical or psychological problem that is likely to have been caused or
exacerbated by the substance.

•

Tolerance.

•

Withdrawal.

Remission might be achieved. Early remission of opioid use disorder is achieved when
after meeting all opioid use disorder criteria, none of the criteria for opioid use disorder have
been met for at least three months but for less than 12 months. The craving or urge to use
opioids criterion might be present and early remission could still be achieved (Strain, 2022).
Strain (2022) described sustained remission as after opioid use disorder criteria were previously
met, none of the criteria for opioid use disorder were met at any time during a period of 12
months or longer. The criteria for craving or urge to use opioids might continue to be present
(Strain, 2022). Maintenance therapy is utilized when a patient is taking a prescribed partial or
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full agonist medication (methadone or buprenorphine) and none of the criteria for opioid use
disorder have been met (Strain, 2022).
Comparable to substance use disorder, Strain (2022) described the severity of opioid use
disorder as
•

Mild - Presence of two to three criteria.

•

Moderate - Presence of four to five criteria.

•

Severe - Presence of six or more criteria.
Potential for Multidisciplinary and Guided Approaches
to Improve Patient Outcomes

Current research suggested patient outcomes may be improved when patients with
chronic pain and opioid use disorder are treated with an integrated pain management or a
multidisciplinary approach combined with conservative pharmacological therapies (Cheng et al.,
2019; Kaye, Jones, Kaye, Ripoll, Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al.,
2017; Manchikanti et al., 2017; Rice et al., 2020; Santini et al., 2021). Integrated pain
management or a multidisciplinary approach utilizes more than one healthcare specialty to
include nutrition, chiropractic, acupuncture/acupressure, physical therapy, psychiatric,
pharmacological, and interventional therapies in the treatment plan. Conservative therapies
include non-pharmacological and non-interventional treatments such as the use of ice, heat,
routine muscle stretching and strengthening, modified activities, and rest. Many of these
treatments could be utilized by patients despite financial or insurance limitations and require
minimal education from the healthcare provider. Pharmacological therapies might include
prescription or non-prescription medications. However, a multidisciplinary and integrated
algorithm, pathway, or standardized protocol for treating chronic non-cancer pain in combination
with substance use disorder or opioid use disorder was lacking both nationally and at the site of
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this scholarly project. The literature suggested more research is needed to adequately treat this
population with evidence-based practices (Kaye, Jones, Kaye, Ripoll, Jones et al., 2017). One
solution may be the development and use of a clinical pathway.
Clinical pathways were developed in the 1980s and are healthcare tools designed to aid in
the translation of evidence-based clinical practice guidelines into streamlined clinical practices
unique to a specific clinical setting (Rotter et al., 2019). Clinical pathways are based on the needs
of a specific environment and for a specific population; they are intended to enhance patient
safety, patient-centeredness, and clinical efficiency. They have historically been used in various
clinical settings, including inpatient and outpatient care, and have a record of reducing
complications and treatment errors. Clinical pathways are structured multidisciplinary care plans
with three distinct characteristics: (a) used when translating guidelines or evidence into a local
healthcare system; (b) detail the steps of treatment into an outlined plan, pathway, algorithm
guideline, protocol, or other action; and (c) standardize care for a specific clinical problem,
procedure, or identifiable need in a specifical population (Rotter et al., 2019).
In the private physician-owned integrated pain management clinic where this project
primarily took place, guidelines from the 2016 CDC (Dowell et al., 2016) and 2017 AISPP
(Manchikanti et al., 2017) guidelines were historically followed when treating patients with
chronic non-cancer pain. An algorithm, pathway, or standardized practice when treating chronic
non-cancer pain in combination with substance use disorder or opioid use disorder was lacking.
There is currently no widely used treatment algorithm or pathway to optimize oral opioid
therapies or multidisciplinary therapies.
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Statement of the Problem
Long-term opioid use might cause adverse effects including opioid dependency and/or
abuse, heroin dependency and/or abuse, overdose, or death. Evidence suggested patients with
chronic pain and substance use disorder, opioid use disorder, or both need an individualized,
holistic, multidisciplinary treatment approach that includes modalities beyond opioids (Cheng et
al., 2019; Dowell et al., 2016; Kaye, Jones, Kaye, Ripoll, Galan et al., 2017; Kaye, Jones, Kaye,
Ripoll, Jones et al., 2017; Manchikanti et al., 2017; Renda & Slater, 2021; St. Marie & Broglio,
2020). Many primary care and chronic pain clinics are ill-equipped to adequately treat chronic
non-cancer pain in patients with concurrent substance use disorder due to the lack of available
clinical guidelines, algorithms, or pathways. The project location specializes in interventional
and pharmacological chronic pain therapies but lacks a specific clinical pathway to treat those
with chronic pain and opioid use disorder, resulting in potentially inconsistent treatment plans.
Purpose of the Project
The purpose of this DNP scholarly project was to develop and validate an evidence-based
clinical pathway to guide clinicians in the management of adult patients who have dual diagnoses
of chronic pain and substance use disorder, specifically opioid use disorder. The intent was to
create a holistic, multidisciplinary, clinical pathway as a guideline to direct healthcare providers
in a pain medicine clinic and in similar care environments where this specific population is
treated in an effort to improve consistency in care while providing individualized care plans.
Need for the Project
Every month, the interventional pain management clinic receives more than 100 referrals
for patients with dual diagnoses of chronic non-cancer pain and substance use disorder (S.
Laurel, personal communication, March 16, 2022). As with national trends, there was a lack of
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evidence-informed, multidisciplinary, and integrative processes and treatment pathways at the
clinic to adequately care for these patients while also controlling opioid prescribing. This DNP
project has the potential to impact current treatment practices for adult patients with chronic pain
and substance use disorder, specifically opioid use disorder. The drafted clinical pathway (see
Appendix A) provides the physicians and advanced practice providers with a consistent,
evidence-based clinical pathway designed to decrease inconsistencies in treatment plans,
improve patient outcomes, and establish provider accountability.
Study Question
This project aimed to answer the following question:
Q1

What integrated therapies derived from a critical synthesis of the literature are
important to a panel of pain medicine clinical experts in the development of a
clinical pathway designed to improve care for adults with dual diagnoses of
chronic pain and opioid use disorder?
Project Objectives

The objectives of this scholarly project were as follows:
1.

Critically evaluate the current literature to determine best practices for the
treatment of patients with dual diagnoses of chronic pain and opioid use disorder.

2.

Using the literature findings, draft a holistic, multidisciplinary evidence-based
clinical pathway tailored to a Midwest interventional pain management clinic that
may be applicable to clinicians in similar practice areas.

3.

Collect and analyze feedback from a panel of experts from the pain medicine
clinic and similar practice areas to validate the clinical pathway and formulate a
plan for future implementation into practice.
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Summary
Death rates and financial losses resulting from the opioid pandemic have led the U.S.
Government to declare the opioid crisis a nationwide public health emergency. However,
millions of Americans suffer from chronic pain, many of whom require a combination of opioid,
conservative, and integrated therapies to manage their chronic pain. Long-term opioid use might
be useful for some patients but the risks include opioid dependency and/or abuse, heroin
dependency and/or abuse, overdose, or death. Federal and state agencies have provided opioid
prescribing guidelines and regulations but they are vague and allow for individual provider
interpretation. Current research points to improved outcomes for those with chronic pain and
opioid use disorder when treated with a multidisciplinary approach combined with conservative
and pharmacological therapies. Despite the evidence, the location of a national or local
multidisciplinary and integrated algorithm, pathway, or standardized protocol for treating chronic
non-cancer pain in combination with substance use disorder or opioid use disorder was not
found. This DNP scholarly project presented a critical analysis of the current evidence, proposed
a clinical pathway designed to guide therapies for those with chronic pain and opioid use
disorder, gathered data from a panel of experts, and finalized the clinical pathway for possible
future pilot testing and implementation.
Definition of Terms
Chronic Non-Cancer Pain and Chronic Pain: Ongoing pain not related to malignancy for
greater than three months.
Conservative Therapies: Non-pharmacological and non-interventional treatments.
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Integrated Pain Management/Multidisciplinary Approach: Chronic pain treatment plan to
include nutrition, chiropractic, acupuncture/acupressure, physical therapy, psychiatric,
pharmacological, and interventional therapies
Interventional Therapies: Invasive procedures to include joint, epidural, and nerve injections or
blocks.
Multidisciplinary: Including more than one healthcare specialty in a patient’s treatment care
plan.
Opioid: A drug class that includes legally prescribed and obtained pain-relieving prescriptions.
These drugs relieve pain by activating opioid receptors on nerve cells in the brain and
body. Morphine, oxycontin, hydrocodone, fentanyl, and heroin are all opioids (National
Institutes of Health, 2020).
Opioid Use Disorder: Opioid use disorder is a medical disease where one misuses prescription
opioids, diverts prescription opioid medications, or uses illicit heroin. This diagnosis
includes opioid abuse and opioid dependency (UpToDate, 2021).
Pathway: A healthcare tool designed to aid in the translation of evidence-based clinical practice
guidelines into streamlined clinical practices unique to a specific clinical setting (Rotter
et al., 2019).
Pharmacology Therapies: Medication management.
Prescription Drug Monitoring Program: An electronic database that tracks controlled
substance prescriptions in a state (CDC, 2021).
Substance Use Disorder: When the recurrent use of alcohol and/or drugs causes significant
impairment that prevents one from completing work, school, or family/home
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responsibilities. Impairment may include health problems or disability (Substance Abuse
and Mental Health Services Administration, 2020).
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CHAPTER II
REVIEW OF THE LITERATURE
Chapter II presents a relevant historical background surrounding opioid prescribing and
the opioid crisis. A review and synthesis of the literature follows. Lastly, a brief description and
rationale for the use of the Stetler (2001) model is discussed.
Historical Background
One of the earliest records of opioids being used as an analgesic was in Europe in the
1600s (Collier, 2018). By the 1860s, American doctors were treating soldiers’ acute pain with
morphine (Georgetown Behavioral Health Institute, 2018). During this time, doctors became
aware of the addictive tendency of morphine. In 1898, the Bayer Company introduced heroin as
a less addictive formulation of morphine (Collier, 2018; Georgetown Behavioral Health Institute,
2018). It was not until the 1910s to1920s that the government placed restrictions on opioids and
formally outlawed heroin (Georgetown Behavioral Health Institute, 2018). The field of pain
medicine was formally founded in the 1960s. Even in the early days of this specialty,
interdisciplinary care team approaches were found to be effective treatments. However,
interdisciplinary approaches were and are expensive and rarely covered by insurance (Collier,
2018).
A 20-year pharmaceutical opioid campaign was started in the early 1980s. During this
era, several prominent pain specialists suggested the incidence of addictive behavior relating to
opioids was low. These specialists in combination with the pharmaceutical campaigns
encouraged medical providers to prescribe opioids freely and without concern for opioid
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addiction (Collier, 2018). In 1995, Dr. James Campbell approached the American Pain Society
declaring pain as the “fifth vital sign” (Scher et al., 2018). A short time later, the Veterans Health
Administration launched a nationwide pain treatment improvement campaign utilizing the unidimensional numeric rating scale (Scher et al., 2018). These efforts suggested pain was a
subjective symptom reportable only by the patient. One year later in 1996, oxycontin emerged on
the market and was touted as non-addicting. Marketing tactics exaggerated the benefits of
opioids while the risks were devalued (American Bar Association, 2021).
In 2002, the Centers for Medicare and Medicaid Services published the Hospital
Consumer Assessment of Healthcare Providers and Systems Survey (Scher et al., 2018). This
survey collected data from a patient’s hospitalization including their perception of their hospital
environment, care provided to them by their healthcare providers, and acute and chronic pain
management. In 2005, the Centers for Medicare and Medicaid Services began correlating a 2%
decrease in reimbursement rates if hospitals failed to report their Hospital Consumer Assessment
of Healthcare Providers and Systems Survey pain management scores (Scher et al., 2018).
Subsequently, hospitals and healthcare providers were pressured to prescribe opioids to ensure
patient satisfaction with their pain management when the Patient Protection and Affordable Care
Act under former President Obama further linked hospital reimbursement rates to patient
satisfaction scores beginning in 2010 (Scher et al., 2018).
Literature Review
Methodology
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINHAHL), and
Google Scholar databases were searched between September 2021 and July 2022. Reference lists
within included articles were also screened for additional sources. Boolean operator “AND” was
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used to combine the following search terms: chronic pain management, substance use disorder,
therapies, and opioid use disorder. Prior to any exclusion filters being applied,10,789 articles
resulted from the above literature search. Inclusion criteria included meta-analyses, practice
guidelines, randomized controlled trials, systematic reviews, articles published in and after 2016,
human subjects, full-text articles, and English language. Articles that were conference abstracts,
solely focused on provider education, or included special study populations such as those
experiencing cancer, acute pain, alcohol misuse, or cannabis use were excluded. Articles with
topics focusing on urine screening tools were excluded as urine drug screenings are currently
known to be best practices in chronic non-cancer pain management and utilized in current
practice. After the exclusion criteria were applied, duplicate records were removed, and articles
from a review of reference lists were added, 21 articles were considered for review (see Figure 1
for the PRISMA Flow Diagram).
The following articles were included in the literature synthesis: 10 systematic literature
reviews (Cheng et al., 2019; Dowell et al., 2016; Howe & Sullivan, 2014; Marshall et al., 2019;
Renda & Slater, 2021; Rice et al., 2020; Santini et al., 2021; Speed et al., 2018; St. Marie &
Broglio, 2020; Voon et al., 2017), three peer-reviewed guidelines (Kaye, Jones, Kaye, Ripoll,
Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al., 2017; Manchikanti et al., 2017), a
semi-structured interview study (Dassieu et al., 2019), a randomized control trial study (Garland
et al., 2019), two expert opinions (Stefanacci & Riddle, 2017; Umberger & Gaddis, 2020), a case
study (Medina et al., 2019), a retrospective review (Patwardhan et al., 2018), a longitudinal
analysis (Scott et al., 2021), and a cross-sectional study (Silva & Anderson, 2021).
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Figure 1
PRISMA Flow Diagram

Identification

Identification of studies via databases and registers

Records identified from:
PubMed (n =10,767)
CINHAHL (n = 148)
Other sources (n =8)

Screening

Records screened
(n =134)

Reports sought for retrieval
(n =2)

Reports assessed for eligibility
(n =128)

Records removed before
screening:
Records removed after filters
applied (n =10,789)

Duplicate records removed
(n =6)

Reports not retrieved
(n =0)

Reports excluded:
Conference abstract (n = 3)
Provider education (n = 6)
Special populations (n= 37)
Cancer/acute pain (n = 54)
Alcohol use and CP (n= 2)
Cannabis and CP (n = 3)
Urine screening tool (n= 2)

Included

[Chronic pain (CP)]
Studies included in review
(n =21)

Level of Evidence
The literature review resulted in five articles with high levels of evidence. The majority
of the articles were assigned evidence levels III-VI. Studies without detailed, small, or limited
sample sizes resulted in the assigned low/lower levels of evidence.
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Sample and Setting
The literature reviews searched PubMed, Embase, Psych INFO, Cochrane Library,
Google searches, Department of Health and Human Services, U.S. Food and Drug
Administration, and the CDC between 2008 and 2018. The systematic reviews obtained literature
between the years 2000 and 2020 and included more than 300 printed publications from
Medline, Cochran Library, Psych INFO, Web of Science, Embase, Google Scholar, PubMed,
CINHAHL, and Cochrane Central Register of Controlled Trials.
Synthesis of the Literature
The synthesis of the literature outlined current best practices for treating patients with
chronic pain. The synthesis of the literature found the only default treatment for those with
addiction diagnoses and chronic pain was opioid therapy (Howe & Sullivan, 2014). A discussion
of non-opioid pharmaceuticals, conservative, and multimodal treatment modalities was also
described.
Chronic Pain Management
Guidelines
Several common themes regarding the management of chronic pain were detected in the
literature. The best practices were primarily based on the 2016 CDC (Dowell et al., 2016) and
2017 AISPP (Manchikanti et al., 2017) guidelines. While there was a plethora of additional
practices for treating chronic pain, treating chronic pain in the presence of substance use disorder
or opioid use disorder was less prevalent. Kaye, Jones, Kaye, Ripoll, Galan et al. (2017) alluded
to this finding by referring to the lack of a single set of guidelines, algorithms, or pathways
capable of identifying and treating those who are at high risk for opioid use disorder with chronic
non-cancer pain.
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The AISPP and CDC guidelines were developed by large expert panels. The large panel
of experts represented a variety of medical, pharmaceutical, academic, and non-academic clinical
fields. The CDC and AISPP ensured the panels were interdisciplinary, represented diverse
geographical areas, and included experts in the management of patients’ chronic non-cancer
pain. Methodologists, epidemiologists, statisticians, and health service researchers with
experience in systematic review research rounded out the panels (Kaye, Jones, Kaye, Ripoll,
Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al., 2017; Manchikanti et al., 2017).
Providers treating patients with chronic pain should recognize that this population
frequently has socioeconomic issues (Dassieu et al., 2019; Scott et al., 2021). The chronic pain
population might experience barriers to care such as reduced access, medication shortages, or
limited, no, or high-deductible insurance coverages. Interventional, multimodal, or
complementary and alternative therapies might not be feasible due to financial hardship. More
research, innovation, and funding are needed to improve treatment outcomes in this population
(Cheng et al., 2019; Dassieu et al., 2019). Most have improved outcomes with individualized,
holistic, multimodal pain treatment plans (Renda & Slater, 2021).
American Society of Interventional
Pain Physicians Guidelines
In 2017, AISPP published guidelines for providers treating chronic non-cancer pain
(Manchikanti et al., 2017). The guidelines were systematic and had the goal of treating chronic
non-cancer pain while decreasing opioid diversion and misuse. The AISPP guidelines could be
summarized as follows: opioid therapy should be reserved for patients who demonstrate a
medical necessity. Opioid therapy should also be used in combination with multimodal therapies
and prescribed at the lowest appropriate dose. When opioids are prescribed, prescribers should
adhere to the recommended monitoring practices (Manchikanti et al., 2017).
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The AISPP guidelines were developed based on quality evidence (Manchikanti et al.,
2017). Upon initiation of opioids, providers are recommended to assess and document the
patient’s pain; they should screen and identify patients at risk for or currently diagnosed with
opioid abuse. Before and during opioid therapy, routine monitoring includes a regular review of
the state’s prescription drug monitoring program and routine urine drug screens. An accurate
physical and psychological diagnosis supported by diagnostic imaging, testing, and evaluation is
recommended. Medical necessity is determined by the patient’s average pain scale and disability.
A patient’s risk for opioid use disorder is given a rating (high, moderate, or low). Treatment
goals should be discussed, established, and based on pain relief, safety, and improved function of
the patient. A provider-patient opioid agreement of compliance was another recommendation
when initiating opioids (Manchikanti et al., 2017).
Routine assessment of the effectiveness of long-term opioid therapy was the second
recommendation by the AISPP (Manchikanti et al., 2017). These recommendations included
regular patient education discussing the effectiveness and consequences of opioid therapy and
short-acting opioid formulations being prescribed at the lowest appropriate dose. Long-acting
opioid formulations should be avoided for initial opioid prescriptions due to the increased risk of
adverse events and reserved for patients with severe intractable pain. Low-dose opioids were
considered up to 40 morphine milligram equivalent (MME), moderate dose 41 to 90 MME, and
the high dose was greater than 91 MME. Methadone was reserved for those who had failed all
other opioid therapies. Regular assessment and documentation of pain relief and functional status
was the best practice (Manchikanti et al., 2017).
During the maintenance phase of opioid therapy, regular monitoring of patients for
compliance, side effects, and medical necessity was recommended (Manchikanti et al., 2017).
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Opioid therapy was best discontinued when side effects were present, therapy was ineffective, or
abuse and misuse were identified. Abuse and misuse could be recognized through the regular
utilization of urine drug screening and review of the prescription drug monitoring program
(Manchikanti et al., 2017).
Centers for Disease Control and
Prevention Guidelines
The 2016 CDC opioid prescribing guidelines were in alignment with the 2012 opioid
prescribing for physicians’ guidelines (Dowell et al., 2016). As of 2022, the CDC is reviewing
the 2016 guidelines. The guidelines identified chronic non-cancer pain management as a
complex issue calling for individualized care. The CDC guidelines preferred
nonpharmacological therapy over chronic opioid therapy for chronic non-cancer pain (Dowell et
al., 2016; Kaye, Jones, Kaye, Ripoll, Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al.,
2017)
The guidelines emphasized that the patient-provider relationship was pivotal and that
therapeutic relationships improved patient outcomes (Dowell et al., 2016). Providers must
balance setting limits with the need to be caring, nonjudgmental, and empathic. Prior to initiation
and during opioid therapy, the risks, benefits, and patient and provider responsibilities should be
clarified. Monitoring of urine drug screen, prescription drug monitoring program, and assessing
for the “three red flags” of potential misuse or diversion (doctor shopping, lost or stolen
prescriptions, and the frequent early opioid prescription refills) were to be routine. If
inconsistency or aberrance was found, a referral to behavioral health and addiction treatment was
appropriate.
Similar to the AISPP guidelines, the CDC recommended a thorough assessment, accurate
diagnosis, risk-benefit analysis, and the routine use of prescription drug monitoring program,
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urine drug screen, substance use disorder, and opioid use disorder screening tools (Dowell et al.,
2016). However, popular opioid treatment agreements were found to be lacking high-quality
supporting evidence. There has not been a widely utilized instrument or protocol for prescribing
opioids. Low effective doses in the immediate release formulations were recommended in the
event of an appropriate diagnosis, pain mechanism, and benefits to risk ratio (Dowell et al.,
2016; Kaye, Jones, Kaye, Ripoll, Galan et al., 2017; Kaye, Jones, Kaye, Ripoll, Jones et al.,
2017). When opioid therapy was prescribed, the preferred dose was less than 50 MME per day.
Before dosing increases, careful consideration must take place and doses greater than 90 MME
per day required justification. To mitigate the risk of opioid therapy, naloxone was recommended
to be concurrently prescribed and available. Co-prescriptions of benzodiazepines and opioids
were not recommended (Dowell et al., 2016).
A multidisciplinary approach including the integration of behavioral health,
interventional, and complementary and integrative therapies was recommended (Dowell et al.,
2016). Multidisciplinary therapies included restorative therapies, behavioral modifications,
physiotherapy, and therapeutic exercise. Interventional therapies included nerve blocks,
radiofrequency ablations, and neuromodulation.
Comprehensive Chronic Patient
Assessment
The first step in treating chronic pain was found to be an assessment of the pain. A
thorough assessment included the location and severity of the pain. A biopsychosocial
assessment described the patient’s ability or inability to perform activities of daily living or
regulate their mood. A complete past medical history was also beneficial in identifying comorbid
conditions (Marshall et al., 2019).
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Utilizing mnemonic tools such as OLDCARTS (see Appendix B) and PEG (see
Appendix C) were beneficial in obtaining a thorough pain history and assessing the severity of
their pain. OLDCARTS is an acronym for onset, location, duration, characteristics, alleviating
and aggravating factors, radiation, temporal pattern, and symptoms associated with pain (Tauben
& Stacey, 2022). The PEG tool (pain intensity, pain interference with enjoyment of life, and
general function) was designed to quantify one’s average pain over the last week, how much pain
had interfered with one’s enjoyment of life, and, lastly, how much pain had interfered with one’s
general function (Tauben & Stacey, 2022).
Evidence-Supported Treatments
Interdisciplinary, physical, and exercise therapies are effective strategies (Marshall et al.,
2019). Patwardhan et al. (2018) found numerical pain scores decreased by 33.8%, daily function
improved, and opioid use decreased by 55.4% when nonopioid medication management and
interventional pain procedures were included in chronic non-cancer pain care plans. Similarly,
nonopioid multimodal medication management was found to be “the cornerstone of care” and
might include several pharmacological classifications (St. Marie & Broglio, 2020, p. 31). Nonsteroidal anti-inflammatory, anti-seizure, antidepressant, topical analgesic, and neuropathic
medication drug classes all have the potential to improve chronic non-cancer pain (Santini et al.,
2021).
Transcutaneous electrical nerve stimulation and complementary or alternative therapies
were also supported by the literature. Complementary or alternative therapies included massage,
acupuncture, exercise, yoga, aquatic therapy, cognitive behavior therapy, mindfulness
meditation, nutrition, online pain self-management education, mind-body control, mindful
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breathing, and nutritional supplementation (Marshall et al., 2019; Renda & Slater, 2021; St.
Marie & Broglio, 2020).
Psychosocial referrals were found to be appropriate for most chronic non-cancer pain
patients. Rice et al. (2020) evaluated a combination of psychosocial and opioid interventions.
The authors found a statistically significant level of pain reduction with the combination of
psychosocial and opioid interventions compared to opioid therapy alone. Psychosocial
interventions in the study included contingency management, counseling, and a community
reinforcement approach.
Substance Use Disorder
Treating chronic non-cancer pain in patients with substance use disorder was found to
have special considerations. There was a known research gap in the role of substance use
disorder on the treatment responses and outcomes of those with chronic non-cancer pain.
Patients with mental health diagnoses and substance use disorder were more likely to experience
chronic pain and were at risk of misusing oral opioid formulations (Marshall et al., 2019). This
population was also more likely to have adverse outcomes from long-term opioid therapy. Thus,
nonpharmacological treatment options were recommended to be included in the chronic noncancer pain treatment plan. The use of suboxone had supporting evidence but the optimal dose
for pain relief was unclear (Howe & Sullivan, 2014; Voon et al., 2017).
Evidence did not support opioids being effective in treating depression, anxiety, or other
psychiatric diseases (Howe & Sullivan, 2014). Treatment of chronic non-cancer pain was better
managed when addiction and other comorbidities were also diagnosed and treated appropriately.
The general consensus of substance use disorder was summarized as an incurable disease that
could be effectively managed using mental health modalities, psychosocial therapies, and, if
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appropriate, medication-assisted treatments (MAT; Medina et al., 2019; Silva & Anderson, 2021;
St. Marie & Broglio, 2020). Medication-assisted treatment is the use of buprenorphine,
naltrexone, or methadone in combination with psychosocial therapies to treat substance use
disorder (UpToDate, 2022).
Successful treatment of this population included a positive, quality patient-provider
relationship in combination with provider addiction training. Patient and family education also
supported improved pain management expectations. Provider education regarding chronic pain,
substance use disorder, and opioid use disorder as chronic diseases decreased stigmas and
treatment biases (Umberger & Gaddis, 2020).
Opioid Use Disorder
Treating chronic pain in the presence of opioid use disorder was a complex issue
requiring special considerations for advanced practice providers. Frequent screenings for opioid
use disorder were recommended. Those most at risk for opioid use disorder included those with
psychosocial, drug-related, genetic factors, mood disorders, physiological diagnoses, and
psychosocial stress (Garland et al., 2019; Kaye, Jones, Kaye, Ripoll, Galan et al., 2017; Kaye,
Jones, Kaye, Ripoll, Jones et al., 2017; Marshall et al., 2019; Renda & Slater, 2021). High-risk
nonmodifiable opioid use disorder risk factors included a young age, back pain, multiple pain
complaints, and substance use disorder. When opioid use disorder was diagnosed, an integrated
treatment plan with medication-assisted treatment in small quantities (prescriptions lasting only a
few days or weeks) and behavioral health therapies were recommended (Dowell et al., 2016;
Kaye, Jones, Kaye, Ripoll, Jones et al., 2017; Marshall et al., 2019; Stefanacci & Riddle, 2017).
Speed et al. (2018) reviewed the outcomes of treating chronic pain and opioid use
disorder with the stepped care model, which was found to have the potential to improve patient
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outcomes in those with chronic pain and opioid use disorder. The stepped care model is an
outpatient behavioral treatment model based on the psychological principles of positive and
negative reinforcement (Speed et al., 2018). Unfortunately, the outcomes from the study were
inconsistent related to significant challenges and limitations of implementing the model and a
lack of reliable and valid outcome measurements.
Mindfulness oriented recovery enhancement reduced the risk of opioid misuse and opioid
use disorder (Garland et al., 2019). Mindfulness oriented recovery enhancement is an integrative
intervention aimed at positively improving psychological health through mindfulness training,
cognitive-behavioral therapy, and positive psychology therapies. In a three-month study followup, the mindfulness oriented recovery enhancement group reported greater reductions in pain
severity and opioid misuse risk and increases in psychological health compared to the control
group (Garland et al., 2019).
Summary of the Literature
As this review of the literature demonstrated, there was no “one size fits all” approach to
the treatment of chronic pain among patients also experiencing substance misuse disorders. Care
plans need to be individualized, multimodal, and integrated in combination with MAT. Positive
patient-provider relationships were found to increase treatment success rates but more research
needs to be performed on the best doses related to medication-assisted treatments for those with
dual diagnoses of chronic pain and substance use disorder and/or opioid use disorder (Medina et
al., 2019; Silva & Anderson, 2021; Umberger & Gaddis, 2020). A pathway designed to treat
chronic pain in those with substance use disorder and opioid use disorder might have been the
missing link in improved patient outcomes and improved consistency of care.
Limitations
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The review of the literature revealed a lack of numerous high-quality research articles.
However, the current review assessed five articles of high quality. Further limitations within the
available research included small sample sizes, not all ethnic groups being represented, and the
average age range being 25 to 74 years old. In addition, guidelines from the CDC (Dowell et al.,
2016) and AISPP (Manchikanti et al., 2017) were geared toward adult, chronic pain patients
without psychiatric diagnoses. Special populations were noticeably left out of the guidelines as
were recommendations for treating those with a combination of chronic pain and substance use
disorder/opioid use disorder.
Implications
Noncancerous chronic pain treatment is a complex issue. There was an identified need for
better recognition, evaluation, and treatment of the mental health diseases that may accompany
chronic pain (Howe & Sullivan, 2014). In addition, the relationships developed with our patients
could be pivotal to their recovery (Silva & Anderson, 2021). Individualized, multidisciplinary,
pharmacological, nonpharmacological, and conservative therapies in combination with opioid
use disorder preventative and treatment measures resulted in the best patient outcomes (Kaye,
Jones, Kaye, Ripoll, Jones et al., 2017; Patwardhan et al., 2018; Renda & Slater, 2021; Santini et
al., 2021; St. Marie & Broglio, 2020). Patient responses to and the likelihood of compliance with
their treatment plan were likely to be affected by their health literacy, culture, and healthcare
access (Scott et al., 2021). Integrated treatment plans in combination with MAT for substance
use disorder improved substance abuse outcomes (Medina et al., 2019). Withholding opioid
prescriptions had the potential to make people who use drugs seek street drugs and heroin, thus
increasing the risk of fentanyl-laced drug overdoses (Dassieu et al., 2019). There was a need for
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education at the provider, patient, and family levels, the public, and policymakers, which would
lead to improved understanding and decreased bias (Cheng et al., 2019).
Theoretical Framework
The framework used to guide this DNP project was the Stetler (2001) model. The
following is a brief overview of the model’s background, description, rationale for selection, and
application as germane to this project.
Background of the Stetler Model
The Stetler (2001) model was first developed as a collaboration between Cheryl Stetler
and Gwen Marram in 1976 while at the University of Massachusetts (Rycroft-Malone &
Bucknall, 2010). The Stetler model was designed to apply research findings into practice while
using critical thinking. It was developed inductively and without any theoretical underpinnings.
The Stetler (2001) model was revised in the 1990s and again in the 2000s (RycroftMalone & Bucknall, 2010). Through the use and revisions of the model, the complexity of the
implementation process was highlighted. It was then that the audience for the model shifted
toward advanced practice nurses who were in positions to promote process changes and utilize
evidence-based practices. The model is currently designed for the implementation and
advancement of knowledge of evidence-based research by individuals and/or teams throughout
an organization’s hierarchy (Rycroft-Malone & Bucknall, 2010).
Description of the Stetler Model
The five phases of the revised model consist of a review of the literature (phase one);
critical analysis and synopsis of the literature (phase two); stated, synthesized, and reported
feasibility of the findings (phase three); a translation of the evidence (phase four); and evaluation
of the project’s achievement of the planned goals (phase five; Stetler, 2001). According to
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Rycroft-Malone and Bucknall (2010), the Stetler model has been the guide for numerous
advanced practice nursing scholarly projects. For example, a neurology nurse utilized the Stetler
model to develop and disseminate nutritional support guidelines for those who had sustained
severe head injuries. Another example was a nurse who adopted a research-based practice to
improve pressure ulcer treatments (Rycroft-Malone & Bucknall, 2010).
Rationale for Model Selection
For this scholarly DNP project, the Stetler (2001) model was chosen based on the logical
flow, transparency, and ease of application of the model into practice. The model had a solid
background of advanced-level practitioners applying the model into research. Lastly, the model
was easily utilized by a single advanced practice provider or group (Rycroft-Malone & Bucknall,
2010).
Application
The Stetler (2001) model was applied to this scholarly DNP project in the following
ways. During Phase I (Preparation) of the Stetler model, the need for a site-specific care pathway
to guide treatment plans for patients experiencing chronic pain with the comorbidity of substance
abuse was recognized. The priority of the development of the pathway was supported by a
thorough review of the literature. Informal feedback from stakeholders (clinic providers and
patients) supported the timely development of such a pathway.
A focused critique and synopsis of the research found during the literature review were
performed during Phase II (Validation). A sufficient amount of quality evidence was identified
through a review of the literature. The evidence was synthesized, resulting in common treatment
themes identified previously in this chapter and in the table of evidence (see Appendix D).
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Phase III (Comparative Evaluation and Decision Making) occurred from a synthesis of
the research. Findings and common themes were identified from the literature synthesis and
evaluated for feasibility for use. The evidence evaluation and feasibility was based on current
best practices, substantiating data, and the overall strength and quality of the evidence.
The clinical pathway was designed for the private pain management clinic using only the
most feasible and highest quality evidence from Phase III. The initial clinical pathway was
drafted from a translation of the evidence in Phase IV (Translation and Application). Together,
the primary investigator and research advisor translated and applied the available findings into
the first draft of the pathway and consulted the scholarly project committee as needed for
support.
Lastly, the draft clinical pathway was disseminated to the group of pain management
stakeholders at the project site during Phase V (Evaluation). Evaluation was performed by
gathering feedback from the pain management expert panel using a validation survey. The
feedback and data collected from the expert panel regarding both feasibility and accuracy
informed subsequent drafts of the pathway. A plan for implementing and testing the care
pathway at the clinical site in the future was proposed.
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CHAPTER III
METHODOLOGY
Chapter III describes the methodology for this Doctor of Nursing Practice (DNP)
scholarly project. The project’s design, setting, sample size, mission, vision, objectives, projected
plan, instrumentation, and data analysis are described in detail. Ethical considerations were not
applicable to patients but were applicable to the surveyed expert panel participants.
Design
This DNP scholarly project consisted of the development and validation of a clinical
pathway based on reported best practices and evidence. The project outcomes being measured
evaluated the drafted clinical pathway for validity, feasibility, and provider utilization.
Interventions were not implemented and patients were not surveyed. By implementing feedback
from the panel of experts, the pathway would more likely be applicable to practice at the project
site and in similar healthcare environments.
Setting
The planned main setting of this scholarly project was a private, physician-owned,
integrated pain medicine clinic in the Midwest. The clinic and medical providers specialized in
chronic pain management in the adult population utilizing multidisciplinary treatment modalities.
Each provider had been trained and was considered an expert in treating chronic pain with
conservative, holistic, mental health, and pharmacological therapies. Other providers in similar
care areas within the professional networks of the researcher and members of the expert panel
were also invited to participate through the snowball method.
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Sample
The project targeted a variety of clinical experts including medical doctors (MDs),
osteopathic medicine doctors (DOs), nurse practitioners (NPs), and physician assistants (PAs)
who practiced at the private, integrated pain medicine clinic. The sample size was six
participants, all of whom met the inclusion criteria of being fluent in English with at least two
years of experience in their current fields, were subject matter experts regarding adult chronic
pain management therapies, and practiced in the pain medicine specialty. The convenience
sample of six study participants did not prove validity but did provide insight into the validity
and future readiness of the proposed clinical pathway for pilot testing. Non-advanced practice
providers such as registered nurses (RNs) or other clinical staff were excluded.
Participation in the scholarly project was voluntary and recruitment occurred using
company email and through the snowball method. Study participants’ addresses were not linked
in any way to the survey responses and thus remained confidential. Study participants could
withdraw at any time free from consequences.
Project Mission, Vision, and Objectives
Mission Statement
The project’s mission was to provide those with dual diagnoses of chronic pain and
opioid use disorder with improved chronic pain management and quality of life through the
development of an evidence-based clinical pathway.
Vision Statement
The vision for the project was to pave the way for future standardized treatment plans
through a holistic, multidisciplinary, patient-centered treatment approach for those with chronic
pain and opioid use disorder.
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Objectives with Steps
1.

The current literature was critically evaluated to determine best practices for the
treatment of patients with dual diagnoses of chronic pain and opioid use disorder.
A review, critique, and summary of the current literature was completed from the
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINHAHL),
and Google Scholar databases and other literature sources. Gaps in care and the
highest level of evidence-based integrated multidisciplinary therapies for patients
with chronic non-cancer pain and opioid use disorder were identified.

2.

Based on the literature findings, a holistic, multidisciplinary evidence-based
clinical pathway tailored to a specific pain management clinic was drafted. In
collaboration with the Project Chair, evidence-based therapies obtained from the
analysis of the literature were utilized to develop a holistic, multidisciplinary
chronic pain management pathway draft.

3.

Feedback from a panel of experts confirming the validity, feasibility, accuracy,
and of the proposed clinical pathway was collected and analyzed.
•

Advanced practice providers (MDs, DOs, NPs, and PAs) who were at-will
participants and met the inclusion criteria were recruited.

•

An anonymous online survey to evaluate the pathway draft utilizing
Qualtrics Survey software was created. The surveys were distributed via
email and consisted primarily of ‘yes’ and ‘no’ questions. Brief openended responses were optional but encouraged.
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•

Data from the Qualtrics survey were exported into an Excel spreadsheet
where edits to the pathway were tracked. The Qualtrics data and openended responses were analyzed in collaboration with the project chair.

•

Pathway edits were implemented based on suggestions from the expert
panel. If consensus was not achieved, the literature was re-consulted, and
the clinical expertise of the primary investigator and Project Chair was
applied.

•

The completed integrated multidisciplinary chronic pain pathway
incorporated all suggested changes from the panel of experts and then was
presented before the scholarly project committee along with a plan for
future pilot testing.
Project Plan

The key components of the scholarly project were as follows
•

Obtained written permission from the project site to conduct the project with the
relevant staff (see Appendix E).

•

Applied to the University of Northern Colorado Institutional Review Board (IRB)
for approval (see Appendix F).

•

Gathered a panel of advanced practice providers (MDs, DOs, NPs, and PAs) who
met the inclusion criteria via a recruitment letter (see Appendix G).

•

Utilized the completed literature review to draft an integrated chronic pain
management pathway in the treatment of adult patients with chronic pain and
opioid use disorder (see Appendix A).
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•

Used Qualtrics survey software to create a ‘yes/no’ validation survey with short
answer options that were highly encouraged for all responses (see Appendix H).

•

Assessment of the clinical pathway by the panel of experts was performed
through a survey to confirm the accuracy, feasibility, potential for provider
utilization, and validity of the proposed clinical pathway.
Instrumentation

The DNP scholarly project employed Qualtrics survey software to virtually disseminate a
survey to the panel of experts. The survey was composed of dichotomous close-ended ‘yes’ or
‘no’ questions (see Appendix H). Brief text responses were highly encouraged but not required
for each question.
Data Analysis
The following data analysis procedures were followed:
•

Qualtrics survey software compiled the survey results. All brief text responses
were analyzed and categorized with the assistance of the project Chair.

•

Data obtained from the surveys were analyzed utilizing qualitative and
quantitative data computations. Modifications to the clinical pathway were
meticulously detailed and tracked under the supervision of the project chair.
Duration

The expected time frame for this scholarly project from the proposal’s defense and
acceptance to the completed project write-up was approximately four months. Once the proposal
was successfully defended and accepted, the creation of the completed clinical pathway draft and
corresponding survey was expected to take two weeks. The clinical pathway and questionnaire
drafts along with the IRB application were submitted. Approval by the IRB took approximately
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two weeks. After IRB approval, the expert panel was recruited. The recruitment process lasted
two to three weeks.
The clinical pathway draft was then administered, and the results cataloged. The expert
panel was given two weeks to complete the survey with a reminder after 14 days. Afterward, the
primary investigator and project chair analyzed the results. Edits to the clinical pathway were
dependent on the questionnaire findings and took an additional one to two weeks. The process
lasted an estimated four weeks.
Lastly, the final chronic pain and opioid use disorder clinical pathway draft, completed
scholarly project write-up, and successful completion of the oral defense took an additional four
weeks.
Ethics
Prior to the initiation of this DNP scholarly project, permission from the project site (see
Appendix F) and IRB approval (see Appendix F) were granted. Consent by the expert panelists
was implied at the start and completion of the questionnaire after the risks and benefits of
participation were explained. The risks of the project included a one-time time commitment of
less than 30 minutes. There were no other anticipated participation risks. Benefits included
contributing to the advancement of advanced medical practice through the creation of a chronic
pain and opioid use disorder clinic pathway. Participation of the expert panelists was strictly
voluntary and they were able to drop out/fail to complete the survey at any time without
repercussion.
A password-protected Qualtrics account was created for the creation of the survey.
Completed surveys and short answer responses were stored in a separate folder on the primary
investigator’s secure and password-protected computer. Results were shared with the project

37
chair via the University of Northern Colorado’s secure server. The survey links were disabled
after the data collection had ceased.
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CHAPTER IV
DATA ANALYSIS AND RESULTS
This Doctor of Nursing Practice (DNP) scholarly project’s survey tool (see Appendix H
was submitted to members of the expert panel and the data were reviewed and analyzed. The
analysis has been broken down specifically for each objective and project question. The results
are presented and discussed in this chapter.
Purpose of the Project
The purpose of this DNP scholarly project was to develop and validate an evidence-based
clinical pathway to guide clinicians in the management of adult patients who have dual diagnoses
of chronic pain and substance use disorder, specifically opioid use disorder. The intent was to
create a holistic, multidisciplinary clinical pathway (see Appendix A) as a guideline to direct
healthcare providers in a pain medicine clinic and in similar care environments where this
specific population was treated to improve consistency in care while maintaining individualized
care plans.
Objectives
The objectives of this DNP scholarly project were met through the utilization of the
Stetler (2001) model, a model designed to apply research findings into practice using critical
thinking. This model was first developed in 1976 with updates in the 1990s and 2000s (RycroftMalone & Bucknall, 2010). The logical flow, transparency, ease of applicability by a single
advanced practice provider or a group, and solid historical backing made this model a logical
choice for this DNP scholarly project.
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The Stetler (2001) model was applied to this scholarly DNP project through the following
five phases: the identified need for a site-specific care pathway to guide treatment plans for
patients experiencing chronic pain with the comorbidity of opioid use disorder (Phase I:
Preparation); a critique and synopsis of the literature resulted in an ample amount of highquality, supportive evidence (Phase II: Validation); a synthesized literature review revealed
common, evidence-based treatment themes (Phase III: Comparative Evaluation and Decision
Making) of which translated into the first draft of the clinical pathway (Phase IV: Translation
and Application); and lastly, the draft pathway was disseminated to a group of subject matter
experts who assessed the pathway for feasibility and accuracy (Phase V: Evaluation).
1.

Critically evaluate the current literature to determine best practices for the
treatment of patients with dual diagnoses of chronic pain and opioid use disorder.

Upon evaluation of the current literature, a guideline, algorithm, or pathway for treating
chronic pain with the comorbidity opioid use disorder was not found. Chronic pain treatment
guidelines have been published by the CDC (2021) and the American Society of Interventional
Pain Physicians (Manchikanti et al., 2017). Both guidelines lacked specific direction for medical
providers when treating special populations including those with opioid use disorder.
Individualized patient care plans with multidisciplinary and integrated therapies
improved patient outcomes. Recommended multidisciplinary plans included behavioral health
(counseling), psychosocial (contingency management and a community approach),
interventional, and complementary and integrative therapies. Other beneficial multidisciplinary
therapies included restorative therapies, behavioral modifications, physiotherapy, and therapeutic
exercise. Interventional therapies (nerve block, radiofrequency ablation, and neuromodulation)
also demonstrated a decrease in chronic pain levels.
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Pharmacological therapies were not recommended as sole therapies but were provided as
part of integrated treatment plans with medication-assisted treatment (buprenorphine, naltrexone,
or Methadone prescriptions written in limited qualities) when appropriate. Non-steroidal antiinflammatory, anti-seizure, antidepressant, topical analgesic, and neuropathic medication drug
classes were found to be pivotal in the improvement of chronic non-cancer pain. Complementary
or alternative therapies such as massage, acupuncture, exercise, yoga, aquatic therapy, cognitive
behavior therapy, mindfulness meditation, nutrition, online pain self-management education,
mind-body awareness, mindful breathing, nutritional supplementation, and transcutaneous
electrical nerve stimulation were also recommended.
Successful treatment plans for this population also included frequent screenings (routine
patient-provider appointments with routine urine drug toxicology screenings); positive, highquality patient-provider relationships; and education. Provider education included chronic pain,
substance use disorder, addiction training, and opioid use disorder. Patient and family education
also improved pain management expectations. Of note, opioids were not effective or
recommended in treating depression, anxiety, or other psychiatric diseases but chronic noncancer pain was better managed when addiction and other comorbidities, such as these, were also
diagnosed and treated appropriately.
2.

Using the literature findings, draft a holistic, multidisciplinary evidence-based
clinical pathway tailored to a Midwest interventional pain management clinic that
may be applicable to clinicians in similar practice areas.

The review of the literature and evidence-based search failed to yield a guideline,
algorithm, or pathway pertaining to the treatment of adult patients with chronic pain and opioid
use disorder. Chronic pain or opioid use disorder-specific guidelines were identified but no
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guidelines had been synergized in the treatment of this population. The literature review
synthesis identified evidence-based practices and similarities in the treatment guidelines for the
two separate diagnoses, and from the guidelines, a clinical pathway designed to treat adult
patients with chronic pain and opioid use disorder was designed. The review and synthesis of the
literature ensured the clinical pathway was derived from evidence-based practices and was
clinically relevant, accurate, and in line with current practice guidelines.
A clinical pathway historically was designed to aid in the translation of evidence-based
clinical practice guidelines into streamlined clinical practices that were unique and easily tailored
to a specific clinical setting. Pathways have been proven to enhance patient safety, patientcenteredness, and clinical efficiency, and reduce complications and treatment errors. The absence
of a clear set of national or local clinical guidelines, algorithms, or pathways has the potential to
result in inconsistent patient outcomes and treatment plans. The result was a streamlined clinical
pathway (see Appendix A) designed as a guide for medical providers when treating patients with
chronic pain in the presence of opioid use disorder.
3.

Collect and analyze feedback from a panel of experts from the pain medicine
clinic and similar practice areas to validate the clinical pathway and formulate a
plan for future implementation into practice.

A panel of subject matter experts versed in the treatment of adults with chronic pain were
invited to participate in this DNP scholarly project. The expert panel included medical doctors,
doctors of osteopathy, nurse practitioners, and physician assistants who were instrumental in
assessing and validating the pathway for accuracy, validity, feasibility, and usability. Providers
who did not treat adults with chronic pain were excluded from the study.
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Medical providers who specialized in chronic pain management in the adult population
utilizing multidisciplinary treatment modalities were the targets of the clinical pathway survey
(see Appendix H). Recruitment of study participants was achieved through the snowball method
of the primary investigator’s and members of the expert panel’s professional networks. Potential
participants were contacted first through an introductory email and were encouraged to forward
the pathway and survey onto colleagues who were medical providers practicing in adult pain
medicine.
The survey was primarily completed by nurse practitioners with a medical doctor and
doctor of osteopathy also participating. Six survey responses were returned completed. Each
participant had experience working with the adult chronic pain population. The participants had
the following years of experience working in their current professions: one (16.67%) had zero to
one years of experience, three (50%) had two to four years of experience, and two (33.33%) had
10 or more years of experience.
The survey was estimated to be completed in less than 20 minutes and members of the
expert panel agreed to participate through the submission of their completed survey. The first
four questions of the survey collected demographic data from the participants, followed by four
yes/no questions used for validation of the pathway with an option for free text comments, and
lastly, two free text comment questions requested additional feedback if any key information was
missing or lacking and if there were any recommendations for improvement not previously
addressed. During the data collection timeframe, eight surveys were submitted but only six were
completed. These six completed surveys were included in the data analysis. Tables 1 and 2 and
Figure 2 provide a visual representation of the expert panel’s demographic data.

43
Table 1
Current Professional Title
Professional Title

n (%)

Medical doctor

1 (16.67)

Doctor of osteopathy

1 (16.67)

Nurse practitioner

4 (66.67)

Physician assistant

0 (0)

Other
0 (0)
_______________________________________________________
Note. N = 6

Table 2
Age of Participants
Age (years)

n

18-25 years

0

26-35 years

1

36-45 years

1

46-55 years

3

56 years and older
1
_____________________________________________________
Note. N = 6
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Figure 2
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Of the completed surveys, 100% (N = 6) found the clinical pathway to be accurate and
reflective of the current standards of practice. One anonymous survey respondent appreciated
“the stepwise interventions that have statistical backing for managing pain with or without
OUD.” The pathway was found to have a logical basis, was reasonable, and was valid by all six
(100%) of the study participants. All six (100%) of the survey respondents found the clinical
pathway to be feasible and easily or conveniently workable.
Despite the survey respondents finding the clinical pathway to be accurate, feasible, and
valid, only 50% (n = 3) reported the willingness to utilize the pathway in practice. The reasons
listed included one provider not feeling like they needed a pathway (16.67%) and another
respondent stated they no longer worked with the specified population (16.67%). The survey
included free text entries regarding any missing key information or improvements to aid the
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pathway in being more applicable to practice. No free text entries, missing key information, or
improvements were submitted. Figures 3-6 visually depict the survey results.

Figure 3
Clinical Pathway Was Accurate and Reflective of Current Literature
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7
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Figure 4
Clinical Pathway Had a Logical Basis or Was Reasonable (i.e., Valid)
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Figure 5
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Figure 6
Respondent Would Utilize the Clinical Pathway in Their Current Practice
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Summary of the Results of the Study Question
The objective of the DNP scholarly project was to answer the following research
question:
Q1

What integrated therapies derived from a critical synthesis of the literature are
important to a panel of pain medicine clinical experts in the development of a
clinical pathway designed to improve care for adults with dual diagnoses of
chronic pain and opioid use disorder?

The question was addressed through a rigorous review of the literature and development
of a survey that gathered data surrounding a proposed pathway from a pain medicine expert
panel. Preliminary data were collected, analyzed, and to address the validity, feasibility, and
usability of the clinical pathway. Based on the data, evaluation plans were established for future
use when the pathway could be successfully translated into clinical practice.
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CHAPTER V
DISCUSSION
In this final chapter, the results of this scholarly project are summarized. The study’s
conclusions, limitations, and recommendations for future research are discussed. A description of
how this Doctor of Nursing Practice (DNP) scholarly project met the American Association of
Colleges of Nursing’s (2006) The Essentials of Doctoral Education in Advanced Nursing
Practice is provided using Waldrop et al.’s (2014) criteria.
Conclusions
The purpose of this DNP scholarly project was to develop and validate an evidence-based
clinical pathway to guide clinicians in the management of adult patients who have dual diagnoses
of chronic pain and opioid use disorder. The intent was to create a holistic, multidisciplinary
clinical pathway as a reference for healthcare providers who specialized in pain medicine or
similar treatment environments where this specific population was treated to provide
individualized, consistent care. The clinical pathway was developed through an extensive review
and analysis of the literature and was then critiqued by a panel of subject matter experts.
This DNP scholarly project was broken into three objectives: Objective I—A review and
analysis of current literature determining best practices for chronic pain and opioid use disorder
treatments; Objective II—Development of a holistic multidisciplinary, evidence-based clinical
pathway; and Objective III—Validation of the clinical pathway by an expert panel. In the future,
a tabletop forum could lead the way for the clinical pathway to be pilot studied in the chronic
pain management clinical setting. The expert panel reviewed the clinical pathway and verified
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the pathway was based on evidence-based practices. The pathway was also considered to be
valid, accurate, and directly relevant to the clinical setting. Three of the survey participants
concluded they would utilize the pathway in their practice. Although given the opportunity, none
of the study participants provided information with regard to missing elements or edits to the
pathway that would improve usability.
Limitations
This DNP scholarly project had several limitations similar to research studies analyzed in
the literature review. Although the Qualtrics survey was sent out to multiple clinical settings and
networks of the expert panel were invited, a limited number of completed surveys were
submitted. Little to no variances in responses and free text responses were found. A more robust
number of responses and free text responses would be anticipated if a larger size across a larger
geographic area was sampled. The length of time to collect the survey responses was limited due
to scheduling constraints and further impacted by the ongoing factors of time, work
commitments, heavy patient care loads, and other miscellaneous factors that might have limited
how many members of the expert panel were able to respond.
Recommendations for Future Research
While this DNP scholarly project successfully met its objective of developing an
accurate, feasible, evidence-based clinical pathway as validated by a panel of experts, more
research is needed. Future research opportunities include presenting the clinical pathway in
person to a panel of experts such as in a round table discussion. The round table discussion
would pave the way for the pathway to be implemented as a pilot study in the integrated pain
medicine clinical setting. A pilot study would be helpful in determining if the pathway resulted
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in consistent treatment plans and how the adult patient population’s (those with chronic pain and
opioid use disorder) outcomes would be affected by the implementation of this clinical pathway.
Reflections on Executing a Successful Doctor of
Nursing Practice Project
The American Association of Colleges of Nursing (2006) envisioned DNP-prepared
nurses bridging the gap between new knowledge and translation, application, and integration of
this knowledge into practice. The American Association of Colleges of Nursing mitigated the
variability in expected outcomes of various DNP programs through development of The
Essentials of Doctoral Education in Advanced Nursing Practice. To satisfy the DNP Essentials,
five criteria must be met (Waldrop et al., 2014). The five criteria are known by the EC as PIE
acronym—each criterion being present and joined together to form a complete “pie”: Enhance,
Culmination, Partnerships, Implements, and Evaluation (Waldrop et al., 2014). This DNP
scholarly project met the EC as PIE criteria as follows:
•

E = Enhance health outcomes, practice outcomes, or health care policy. This DNP
scholarly project involved the development of a clinical pathway designed to
guide medical providers in treating adult patients with dual diagnoses of chronic
pain and opioid use disorder to improve health outcomes and treatment
consistencies. After a review of the literature, such a pathway or guideline was
not found, although guidelines for each diagnosis were identified. This scholarly
project was found to be very timely due to the current opioid pandemic’s financial
liabilities and deadly consequences.

•

C = Reflect a culmination of practice inquiry. A culmination of practice inquiry
was evident when an informal investigation revealed patients with chronic pain
and opioid use disorder were either not being treated by pain medicine specialists
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or, if they were, the treatment processes were inconsistent between providers in
the same practice setting. An extensive literature review and synthesis were
utilized in the development of an evidence-based clinical pathway guiding
medical providers to systematically treat the population with evidence-based
practices. The theoretical framework of the Stetler (2001) model provided a
proven method of literature evaluation and implementation to influence change in
the clinical setting.
•

P = Require engagement in partnerships. Partnerships with the graduate
committee and the subject-matter expert panel were crucial throughout the
planning and execution of this DNP scholarly project. Partnerships were pivotal in
engaging and recruiting a panel of experts who had direct interests when treating
the patient population. The expert panel was key in ensuring the clinical pathway
was an accurate reflection of current practice guidelines, was valid, and was
feasible in the pain medicine practice setting. The pathway’s completeness was
assumed when the submitted survey responses lacked any open text responses
suggesting a lack of data or areas of improvement.

•

I = Implement/apply/translate evidence into practice. While reviewing and
synthesizing the literature, no clinical practice pathway or guideline could be
found when treating patients with dual diagnoses of chronic pain and opioid use
disorder. The deadly opioid pandemic and nationwide public health opioid
emergency provided the narrative as to why the creation and development of such
a pathway was needed. The clinical care pathway was validated by an expert
panel of pain medicine providers.
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•

E = Requires evaluation of health care, practice, or policy outcomes. This DNP
scholarly project was formatively and summatively evaluated as recommended by
the Stetler (2001) model. The expert panel analyzed the clinical pathway for
accuracy, validity, and feasibility prior to implementation in the clinical practice
setting. The expert panel were medical providers specializing in treating adults
with chronic pain and opioid use disorder. A Qualtrics survey questionnaire was
utilized to obtain the evaluations.
Summary

The financial and death losses from opioids have brought national attention to the opioid
pandemic. Despite national and state guidelines to treat chronic pain, a guideline, algorithm, or
pathway was not found to treat adult patients with chronic pain in the presence of opioid use
disorder. This DNP scholarly project sought to bridge the gap in care and develop a clinical
pathway as a guide and reference for medical providers who treat adult patients diagnosed with
chronic pain and opioid use disorder.
This scholarly project met the American Association of Colleges of Nursing’s (2006)
DNP Essentials through the meeting of three objectives: Objective I—A review and analysis of
current literature determining best practices for chronic pain and opioid use disorder treatments;
Objective II—Development of a holistic multidisciplinary, evidence-based clinical pathway; and
Objective III—Validation of the clinical pathway by an expert panel. A panel of subject matter
experts found the pathway to be accurately based on current evidence-based practices that were
valid and relevant to the clinical setting. Future recommendations would be to hold a roundtable
forum and complete a pilot study with the clinical pathway in the clinical practice setting to
improve patient outcomes and care plan consistency.
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APPENDIX A
AN ADULT CHRONIC PAIN AND OPIOID USE
DISORDER CLINICAL PATHWAY
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APPENDIX B
OLDCARTS MNEMONIC
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Mnemonic for chronic pain symptom assessment and historical documentation template:
•

Onset- When did your pain start?

•

Location-Where does it hurt?

•

Duration-How long does your pain last?

•

Character-How does your pain feel? i.e., aching, burning, shooting, tingling

•

Alleviating/Aggravating and Attribution- What makes your pain better/worse? What do
you think is the cause?

•

Radiation-Does this pain spread anywhere else?

•

Temporal pattern-Does your pain vary over the course of a day?

•

Symptoms associated-How does your pain impact your physical function, your mood,
and your sleep?
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APPENDIX C
PEG MNEMONIC
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Pain Intensity, Pain Interference with Enjoyment of Life and General Function (PEG)

On a scale of 0 to 10 with 0 being the lowest and 10 being the highest
•

What number (0 to 10) best describes your pain on average in the past week?

•

What number (0 to 10) best describes how, in the past week, pain has interfered with your
enjoyment of life?

•

What number (0 to 10) best describes how, in the past week, pain has interfered with your
general function?
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APPENDIX D
TABLE OF EVIDENCE
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Table D.1
Table of Evidence
Author
(Year)
Cheng et
al. (2019)

Level of
Evidence
Level VII: a
panel of
experts with
thousands of
testimonialssuggest higher
grade
Editorial
published by
Pain
Management
Best Practices
Inter-Agency
Task Force
chair and
members

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Mandated
by
Congress to
review
chronic
pain (CP)
best
practices
and
identify/add
ress care
gaps

Not
reported

Literature
review

- Task force:29
members with
representatives from
federal agencies and
nonfederal experts
- Experts: pain
management,
addiction, mental
health

- Acute/chronic
pain environmental
scan
- Reviewed
medical/scientific
data
- Patient (pt)
testimonials
- Public comment
- Testimony from
experts

Patient (pt)
centered/individualized care
1. thorough assessment
2. accurate diagnosis (dx)
3. risk-benefit analysis prior to
interventions
4. screening/dx tools: prescription
drug monitoring program
(PDMP), urine drug screen
(UDS), identify pt at high risk for
substance use disorder (SUD) and
overdose (OD)
“State of the art” chronic pain
management
1. multidisciplinary approach:
restorative therapies-selfmanagement, behavioral
modifications, physiotherapy,
therapeutic exercise
2. pharmacotherapies is dx and
pain mechanism appropriate
3. interventional: nerve blocks,
radiofrequency ablation (RFA),
neuromodulation
4. behavioral health
5. complementary and integrative
therapies: acupuncture, massage,
movement therapies (yoga, tai
chi)
Access to care: staffing and med
shortages, limited insurance
coverage, CP and SUD stigmas
Provider/pt/public education: CP
is a disease-education/training at
all levels
Innovation/research: research
funding

Biases of CP and SUD
Improved education/training
from public, patient,
provider, and policy makers
Misapplication/misinterpreta
tion of guidance
Use guidelines as suchindividualized care with
special populations being
geriatric, prenatal, cancer,
pediatric, SUD
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Table D.1 Continued
Author
(Year)
Dassieu et
al. (2019)

Level of
Evidence
Level VIsmall
sample size
in one city

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

-Guidelines
leads to fewer
treatment (tx)
options for
people who
use drugs
(PWUD) w/
chronic noncancer pain
(CNCP)
-Examine
PWUD’s
experiences
during the
opioid crisis

Thematic
analysis
framework

Semistructured
interview
with openended
questions

- Montreal, Canada
within an institution
July 2017-May
2018
- 25 study
participants
- Ages 27-61 y/o
- 10 women
- 15 men
- All current
polysubstance
abusers
- Dual CNCP
lasting 3 months or
longer
- All Frenchspeaking, at least 18
y/o, and able to give
informed consent

-Interviews done by
the first author: lasted
40-90 min
Digitally recorded &
transcribed
-Semi-structured guide
w/ open questions:
CNCP experience,
evolution,
management, the
trajectory for CNCP
management, and
lifetime drug use
-NVivo 9 software
analyzed data
-Interview transcripts
coded to identified
themes
-Memos identified
emerging patterns

PWUD felt stigmatized and
faced inequalities when
accessing CNCP tx

A small study in Montreal,
Canada

CNCP therapies physician
preference
Socioeconomic factors
prevent access to CNCP tx:
lack of incomeunemployment, poverty
Integrated therapies too
costly for this population
Prescribed opioid (PO)
guidelines limited
medication therapies when
in combination with PWUD--PWUD then seek street
drugs or heroin to selfmedicate

Interviewees perceived risk
of poor recall or fear of
biases
Withholding PO has the
potential to make PWUD
seek street drugs and heroin
thus increasing the risk of
fentanyl-laced drug OD
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Table D.1 Continued
Author
(Year)
Dowellet
al. (2016)

Level of
Evidence
Level I

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Provide
primary care
providers
with
guidelines
when
treating noncancer
chronic pain

Grading of
Recommen
dations
Assessment
,
Developme
nt, and
Evaluation
(GRADE)

Systematic
literature
search and
contextual
evidence
review

Not available in this
text-details “may be
found in the Morbidity
and Mortality Weekly
Report (MMWR)
and associated online
appendixes”

-CDC developed a
committee
-Committee drafted
guideline
recommendations
after feedback was
obtained from
experts, primary care
professional society
representatives,
and state agency
representatives
-Guideline peerreviewed

1. Nonopioid therapy and
nonopioid pharmacological
therapy is preferred tx for CP
2. Opioids are only used when
benefits outweigh the risks
3. Prior to and during tx discuss
known risks, benefits of opioid
therapy, and pt/provider
responsibilities
4. Immediate release (IR)
formulations when starting
opioid therapy
5. Prescribe lowest effective
dose, careful consideration
before increasing dose to more
than 50 morphine milligram
equivalents (MME) per day,
avoid more than 90 MME per
day, justify decision when
dosing 90 MME or more per day
6. Opioids for acute pain: lowest
effective dose for shortest amt of
time; 3 or less days sufficient;
more than 7 days rarely needed
7. Discuss risks/benefits 1-4
weeks after starting or increasing
opioids
8. Before and during opioid
therapy mitigate risk by offering
naloxone
9. Regular review of PDMP
10. Prior to and during opioid
therapy UDS testing
11. Avoid concurrent opioid and
benzodiazepine use
12. Medication-assisted tx
(methadone or buprenorphine) in
combination with behavioral
therapies for OUD

Implications and
Limitations
-Improve pt and provider
communication i.e.,
benefits vs risk of
opioids
-Improve safety and
effectiveness of tx plan
-Reduce risks of longterm opioid therapy.
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Author
(Year)
Garland et
al. (2019)

Level of
Evidence
Level I

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

-Conduct a
randomized
control trial
(RCT) and
analyze the
data
of
MindfulnessOriented
Recovery
Enhancemen
t (MORE)
-An
integrative
intervention
to improve
positive
psychologica
l health

Mindfulnes
s to
Meaning
Theory

RCT

-Salt Lake City, UT
-Over 2 years: 304 pt
screened
-N=95 pts w/ opioid tx
CP
-age=44-68 y/o mean
56.8
-70 completed tx, 72
completed post-tx
measures, and 48
completed 3-month FU
-Patients with COMM
scores <13 were
included in the trial
-Inclusion criteria: pain
on more days than not,
noncancer causes,
prescribed and taking
opioids every day (QD)
or nearly QD for the
past 90 days
-Exclusion criteria:
actively suicidal,
psychotic, or had
previous mindfulnessbased intervention

-Participants
randomized to 8
weeks of therapist led
MORE or Support
Group (SG)
-Opioid misuse risk
assessed at baseline
using
Opioid Misuse
Measure: scores less
than 12 included in
the trial. Patient
- Mini-International
Neuropsychiatric
Interview 6.0 assessed
for comorbid
psychiatric dx
-MORE:
mindfulness training,
third-wave cognitivebehavioral therapy,
and principles from
positive psychology
into
-Measures:
positive affect,
meaning in life, selftranscendence,
-Post tx changes in
pain severity and
opioid misuse risk
measured at 3 months
post-intervention

-MORE participants
significantly greater reductions
in pain severity and opioid
misuse risk at 3-month follow-up
compared to SG participants
-MORE group significantly
greater increases in positive
psychological health thus
predicting less opioid misuse
risk by follow-up

Implications and
Limitations
-Interventional therapies
including positive
psychological
mechanisms (MORE)
may reduce opioid
misuse risk in the CP pt
using long-term opioid tx
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Table D.1 Continued
Author
(Year)
Howe &
Sullivan
(2014).

Level of
Evidence
Level IV

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Review the
data and
analyze the
roles of
psychiatric
disorders in
opioid use
and abuse in
pt with CP

Not
reported

Literature
review

PubMed search

-Key phrases “chronic
pain” and “opioid
therapy”
-Inclusion criteria:
articles with topics on
the epidemiology of
comorbidity between
chronic pain and
psychiatric
disorders, trends in
long-term opioid
therapy, clinical trials
using opioid therapy
for
CP or mental health
dx

-Parallel increases in opioid
therapy for noncancer CP and
opioid misuse and abuse.
-CP is a common comorbid
condition with psychiatric dx
-Pts w/ mental health and
SUD more likely to have CP tx
with long-term opioid therapy &
more
likely to have adverse outcomes
from long-term opioid therapy
-Very little evidence to support
opioid tx providing a brief
antidepressant and
anxiolytic effects in patients with
depression or anxiety
-Very little evidence of longterm benefit of psychiatric dx
treated with opioids

Kaye,
Jones,
Kaye,
Ripoll,
Galan et al.
(2017)

Level II

To review
the current
knowledge
base
surrounding
the OUD,
risk factors,
and
preventing,
assessing,
monitoring
OUD in pt
with CNCP

Not
reported

Review of
2016 CDC
and 2012
Pain
Physician
opioid
guidelines
by experts
on the
panel

Expert panel review

Expert panel review

-Nonpharmacologic therapy
preferred to chronic opioid
therapy (COT) for CNCP
-Polysubstance use and tx is
underutilized
-PO lowest effective dose in IR
if benefits outweigh the risks
-Pts are most at risk for OUD
when they have 3 factors
present: psychosocial, drugrelated, and genetic
-Primary sources of street
opioids are from the elderly, pts
with pain, “doctor shoppers”, pill
brokers/dealers
-High-risk nonmodifiable factors
young age, back pain, multiple
pain c/o, and SUD
-Hx of mood disorder,
psychological dx, and
psychosocial stress increase the
risk for OUD

Implications and
Limitations
-Opioids may be the only
default psychiatric
treatment for
patients with CP
-Unmet need for better
recognition, evaluation,
and tx of mental health
problems in pt with CP

-Nonpharmacy therapy
preferred tx for CNCP
-Polysubstance tx
-Opioids if benefits
outweigh the risk
-Psychosocial, drugrelated, genetic, mood
disorder, psychological
dx, and psychosocial
stress are factors noted
with increased risk for
OUD
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Continued
Author
(Year)

Level of
Evidence

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and
Limitations

Kaye,
Jones,
Kaye,
Ripoll,
Jones et al.
(2017)

Level II

Continuation
of part 1

Not
reported

Review of
2016 CDC
and 2012
Pain
Physician
opioid
guidelines
by experts
on the
panel

Expert panel review

Expert panel review

-Not one single set of guidelines
or tools capable of identifying
CNCP who are high risk for
OUD: “at-risk” pts small
quantities of PO i.e.
days/weekly prescriptions
-Provider needs to be caring,
nonjudgmental, and empathic
but set attainable limits and tx
goals
-No widely used
instrument/protocol to optimize
PO therapy
-UDS-inconsistent results then
referral to behavioral/addiction
tx
-PDMP monitoring
-Opioid tx agreement- lowquality evidence for support of
-3 red flags to potential misuse
or diversion: doctor shopping,
lost prescriptions, early refill
requests
-Integrated approaches for those
with CNCP and OUD

-Complex issue:
individualized, safe PO
with OUD preventative
measures

To review
the current
knowledge
base
surrounding
the OUD,
risk factors,
and
preventing,
assessing,
monitoring
OUD in pt
with CNCP
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Author
(Year)
Manchikanti
et al. (2017)

Level of
Evidence
Level IIAmerican
Society of
Intervention
al Pain
Physicians
(AISPP)
guidelines

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Provide a
systematic
and
standardize
d approach
for
providers to
appropriatel
y prescribe
opioids for
pts with
noncancer
related CP
while
reducing
the risk of
opioid
diversion
and/or
misuse

Not
reported

Guidelines
based on a
comprehe
nsive
literature
review of
current
evidence
by a panel
of
multidisci
plinary
experts,
expert
opinion,
and
stakeholde
r input

-PubMed, Cochrane
Library, Google
searches, and Dept of
Health and Human
Services, FDA, CDC
websites searched
-Search terms:
opioids, chronic
opioid therapy in
noncancer pain,
opioid therapy
effectiveness,
adverse
consequences,
preventative
strategies,
monitoring,
balancing opioids
therapy and abuse

1. The National Guideline
Clearinghouse Extent
Adherence to Trustworthy
Standards (NEAT) followed
2. Panel of experts from
different medical and
pharmaceutical fields
reviewed literature and
drafted recommendations
3. Public reviewed draft
document. Their comments
were requested and
considered

1. Initiating opioids
Evidence: Level I
-Accurate assessment and
documentation of pain
-Accurate diagnosis
Evidence: Level I-II
-PDMP
-Assess and rate OUD risk
Evidence: Level II
-UDS
- Establish and document
medical necessity.
-With pt establish tx goals
based on pain reduction and
improvement in
function/ADLs.
Evidence: Level II-III
-Screen and identify pts
for/with opioid abuse
Evidence: Level III
-Consider imaging, testing,
and evaluations to support
physical dx and subjective
symptoms
-Opioid agreement with
compliance
2. Assessment of
Effectiveness of Long-Term
Opioid Therapy
Evidence: Level I
-Initiating opioid therapy
avoid long-acting opioids
-Methadone after the failure
of opioid therapy
-Patient education regarding
the effectiveness and
adverse consequences of
opioids
-Long-acting or high-dose
opioids only in specific
circumstances with severe
intractable pain.
Evidence: Level I-II
-Long-acting and shortacting opioids have similar
efficacy but increased

-Opioid tx should be reserved
for those with medical
necessity, in combination with
multimodal therapies, and
prescribed with the lowest
appropriate dose
-If opioids prescribed adequate
monitoring practices should be
followed
-Medical necessity defined as
pain scale average of ≥ 4 on a
scale of 0 – 10 and/or disability
-Methadone prescribed by
specially trained provider
within FDA recommended
dosages
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adverse events of longacting
Opioids
Evidence: Level II
-Start opioid therapy with
the lowest appropriate dose
and short-acting
formulations
-Routinely assess pain relief,
functional status
improvement of ≥ 30%, and
adverse consequences
3. Monitoring for
Compliance and Side
Effects
Evidence: Level I
-Assess for and tx side
effects
-EKG routinely for
methadone pts
Evidence: Level I-II
-Utilize UDS and PDMP to
assess for compliance,
misuse/ abuse.
4. Maintenance Phase
Evidence: Level I-II
-Regular monitoring of
medical necessity
Evidence: Level III
-Discontinue opioid therapy
when ineffective, adverse
consequences, and abuse
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Table D.1 Continued
Author
(Year)
Marshall et
al. (2019)

Level of
Evidence
Level III

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Provide
resources to
providers
regarding the
assessment,
diagnosis,
and tx for CP
Tx including
opioids and
multidiscipli
nary
therapies

Not
reported

Literature
review and
expert
opinion

Literature review criteria
not published

-Role of chronic
pain
-Opioids and
mechanisms of
action
-Opioid tx for CP
-CP and opioid
dependence
-Traditional tx of
opioid dependence
-Psychosocial
interventions for CP
and opioid
dependence

1. Assess CP including location
and severity
2. Biopsychosocial assessment
-Are ADLs affected? How
much?
-Trouble regulating mood?
3. Comorbid conditions
(including psychological and
social problems)
4. Psychosocial referral
5. Careful consideration of
opioids for CP. If mental health
diagnosis (dx) present an
increased risk of opioid abuse
and/or use of illegally obtained
opioids
6. If pt misuses opioids, the level
of addiction or dependency
needs to be assessed.
Medication-assisted therapy,
psychiatric referral, and exercise
regime recommended tx
7. Interdisciplinary tx (including
psychosocial therapies) approach
widely successful for CP tx

Implications and
Limitations
-CP requires an
interdisciplinary tx
approach including a
biopsychosocial
component

76
Table D.1 Continued
Author
(Year)
Medina et
al.
(2019)

Level of
Evidence
Level VI

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Provide
“exemplar”
example of
tx of a pt
with CP and
OUD

Not
reported

Case
study
review

-50-year-old African
American being tx at
integrative care
Federally Qualified
Health Center
-Discharged from
rehabilitation center 3
months ago
-Admitted into the
center x 2 years after
above the right knee
amputation related to
venous insufficiency
following a cardiac
event
-Routine opioid tx for
the past 2 years; once
discharged sent home
with a non-narcotic
prescription
-Using illegally
obtained opioids from
the street
-No benzos but
positive for cannabis
-Dx with OUD

Case study review
1.
Multidisciplinary
tx team
-FNP
-Behavioral health
provider
-PMHNP
2. Goals of tx plan
-OD prevention
-Withdrawal
management via
COWS scale
-CP tx
-During medical
detox started on
Suboxone 8mg-2
mg film BID
[medication
assisted treatment
(MAT)]

Patwardha
n et al.
(2018)

Level III

Evaluation if
fellowshiptrained pain
specialists
reduce pain
and opioid
use in those
with chronic
noncancer
pain

Not
reported

Retrospec
tive
Review

-Banner-University
of Arizona
Medication CenterSouth Campus
outpatient pain clinic
-July 2014-January
2016
-1,268 charts
reviewed
-296 charts chosen
-Average age 58.6
y/o
-40.6% of sample
size men
-Inclusion criteria:
currently on opioid tx
for noncancer
chronic pain

-Selected pts started
on nonopioid
medication
management and
interventional pain
procedures
performed
-Pre/postintervention pain
levels measured
using the Numerical
Rating Scale (NRS11)

Study Findings

Implications and Limitations

-Follow CDC guidelines for CP tx
-Build trusting relationships with pt
-Integrated care plan with MAT

-Years of providers
prescribing opioids (which we
thought were safe) has
increased the number of pt
with OUD
-Integrated tx plan with MAT
for SUB improves substance
abuse outcomes

-NRS-11 scores decreased by 33.8%
(from 6.8/10 to 4.5/10)
-Number of pain episodes decreased
-ADLs improved (sleep, work, and
chores)
-Opioid use decreased by 55.4% (from
53.8MME/day to 24MME/day)

-The study population
continues with chronic pain
management and their pain
may continue to evolve.
-This study lacks details
regarding the population’s
type of pain, age, gender, and
duration of opioid tx
-Importance of nonopioid
treatments and therapies
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Table D.1 Continued
Author
(Year)
Renda &
Slater
(2021)

Level of
Evidence
Level III

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Provide
comprehensive
interprofessional
CP therapies to
decrease the risk
of side effects
and addiction

Not
reported

Literature
review of
evidencebased CP
medicatio
ns and
treatments

Literature review
sample criteria not
reported

Literature review
methods not
reported

1.Pts w/ CP need individualized and
holistic multimodal pain treatment
plans
2.Multimodal analgesia
-NSAIDS, antiseizure,
antidepressants, topical medications,
and complementary/alternative
therapies
3. Physical therapy
4. Transcutaneous electrical nerve
stimulation
5.Complementary/alternative
therapies
-massage, acupuncture, exercise,
yoga, aquatic therapy, cognitive
behavior therapy (CBT), mindfulness
meditation, nutrition, breathing
exercises, and supplements

-Assess pain routinely after
initial assessment
-Utilize nonopioid therapies
as appropriate
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Author
(Year)
Rice et al.
(2020)

Level of
Evidence
Level I

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Discuss most
appropriate
psychosocial
interventions
for those
with CP and
OUD

Bayesian
Framework

Systematic
review with
a network
metaanalysis

-Search for RCT in
June 2020
-MEDLINE,
Embase, PsycINFO,
and the Cochrane
Central Register of
Controlled Trials
searched
-17,755 citations
found
-184 citations from
reference lists added
-813 abstracts found
to be relevant
-72 of the 813 RCT
met inclusion criteria
-Search terms:
“opiate substitution
treatment”, “opioidrelated
disorders/drug
therapy”,
buprenorphine/therap
eutic use”, “opioid
maintenance”,
“methadone
substitution”
-Conference abstracts
dated before 2016
and dissertation
abstracts removed

-Databases searched
using Distiller SR
Software
-Cochrane RoB tool
evaluated articles for
bias risk

1. Only 48 RCT with 20
interventions and 5,404 participants
were found to be statistically
significant when psychosocial
interventions were used in
combination with opioid therapy
rather than opioid therapy alone
2. A rewards-based intervention was
superior to stand alone opioid
therapy
3. The remaining 24 RCT found no
statistically significance between
opioid tx and a combination of
opioid tx an psychosocial
interventions
4. Due to variabilities and
differences in finding formats only
treatment retention was able to be
analyzed using NMA methods.
5. Rewards-based interventions in
combination with opioid tx more
effective than opioid tx alone
-contingency management
-counseling
-community reinforcement approach
6. Most RCT did not find
psychosocial therapies added to
opioid tx to decrease opioid use

-Special populations not
included in most RCT
-Many of the populations
were identified as having or at
risk for OUD
-Psychosocial interventions
most helpful for female pts
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Table D.1 Continued
Author
(Year)
Santini et
al.
(2021)

Level of
Evidence
Level I

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

-Review of
effective
multimodal
approaches to
treat Veteran’s
chronic
musculoskeletal
pain and pain
related
syndromes

Stepped
Care
Model

Systematic
review

-Searches resulted in
228 papers: after
screening 24 articles
-Combined sample
11 million
-Mean age 57.67y/o
-85.26% male
-70% Caucasian
-22.88% African
American
-7.12% other
-88.02% had higher
education levels
-11.98% high school
level education

-Quantitative studies
went through the
CONSORT and
STROBE quality
checklists
-Review of Cochrane
Library, PubMed,
CINHAHL, and
Psych INFO between
2001-2020
-Keywords: “veteran”
“chronic
musculoskeletal
pain,” “posttraumatic stress
disorder/
PTSD,” “treatment,”
“Afghanistan,”
“Iraq/Irak,”
“military operations,”
and “noncancer”
-Exclusion criteria:
languages other than
English or Italian,
case reports,
editorials, conference
abstracts, doctoral
thesis, pediatric,
geriatric, or general
populations, and
cancer pain

-Veterans high prevalence of
musculoskeletal pain (81.5%) with
comorbidities
68.2% PTSD
66.8% post-concussive symptoms
(PPCS)
-With presence of comorbid dx of
PTSD and PPCS transdisciplinary
approach in combination of
mitigating negative effects of
opioids

-Since only English and
Italian articles reviewed,
other nation’s may have
differing results
-Multimodal approach “must
be implemented”
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Author
(Year)
Scott et al.
(2021)

Level of
Evidence
Level III

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Evaluate how
the use of
complementar
y health
approaches
changes over
time and how
sociodemogra
phic factors
change the use

Andersen
Model

Longitudinal
analysis

-Midlife in the
United States
-English speaking
adults, 25-74 y/o, in
the 48 contiguous
states, with at least
one telephone
-Three “waves” or
surveys sent out
1. First wave
-1995-1996
-6,325 individuals
2. Second wave
-2004
-4,041 individuals
-average FU was 9
years
3. Third wave
-2013
-2, 717 individuals

-Sample completed
interview and a selfadministered
questionnaire
-Exemption from the
Institutional Review
Board was granted
-Sample surveyed if
they used
chiropractic, herbal
therapies, meditation,
or massage therapy
for tx of physical,
emotional, personal
problem,
maintain/enhance
wellness, or prevent
chronic illness
-Independent
variables: sex, age,
race, education (high
school, GED,
associate, bachelor,
or advanced degree),
spirituality,
depression, marital
status, household
income, and health
insurance
-Qui-square analysis
tested relationships
between variables

-25%-38% of those surveyed
continued therapies from one wave
to the next
-26%-39% discontinued use
-30% lost from one wave to the next
-Age, spirituality, and previous use
significantly associated with new
therapeutic uses from one wave to
the next
-Age and education level are
significantly associated with
cessation of chiropractic use

-Sample population ages 2574y/o only
-Hispanic population not
included in the survey
-English speaking only
-Health literacy, culture, and
health care access may affect
the use of these modalities
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Author
(Year)
Silva &
Anderso
n (2021)

Level of
Evidence
Level VI

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Psychosocial
therapies
combined with
MAT for OUD
has proved to
increase
continued tx;
study to analyze
what factors help
to sustain
recovery and
what effects does
long-term opioid
therapy have in a
pt’s life to
prevent relapses

Ajzen’s
Theory of
Planned
Behavior
and
Maslow’s
Theory of
Needs

Crosssectional
and
convenien
ce
sampling

-Swedish clinic
-118 potential
participants
-Convenience sample
of 19 patients; all of
whom were
prescribed MAT for
OUD by the clinic

-Semi-structured one
on one interview
broken down into
three phases

-As adolescents, all participants
experimented with drugs and had
periods of substance use, treatment,
desistance, recovery, and replace
-Perceived pt stages
1. pretreatment stage
2.Treatment stage
3. MAT
-Pt perceive stigma difficult to
manage
-Quality relationships led to
sustained recovery

-Small Swedish study of
convenience
-Less than 30% female
participants
-The relationships we develop
with our patients could be
pivotal for our patient’s
recovery

Speed et
al.
(2018)

Level V

Provide
evidence-based
assessment,
formulation, and
tx of pts with CP
and OUD

Not
reported

Literature
review

-From 2008-2018
literature search in
PubMed, Embase,
and Psych Info
-Keywords pain or
chronic pain and
opioid-related
disorders, opiate,
methadone,
buprenorphine,
naltrexone,
opioid abuse, opioid
misuse, opioid
dependence, heroin
addict, heroin abuse,
heroin
misuse, heroin
dependence, or
analgesic opioids,
and stepped care,
integrated services,
multidisciplinary
treatment, or
reinforcement-based
treatment.

-Methodology of the
literature review is
missing from this
article

-Stepped care models have the
potential to improve outcomes

-Limited tx options for those
with CP and OUD
-Inconsistent outcomes with
stepped care models
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Author
(Year)
Stefanacci
& Riddle
(2017)

Level of
Evidence
Level VII

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

Expert
recommendation
s on prescribing
opioids

Not
recorded

Expert
recommen
dations

Expert opinion, no
setting or sample

No survey or
instruments used
though current CDC
guidelines are
followed

-Initiate opioid doses low and go
slow; IR recommended over ER
-During opioid therapy frequently
reassess benefits vs risks; UDS
-Screen for OUD; if OUD present tx
with MAT

-Guidance for marijuana
prescribing listed
-Marijuana and opioid tx not
recommended for CP

St. Marie
& Broglio
(2020)

Level VI

Guidance for
acute and
outpatient
providers to
manage pain in
the presence of
OUD

Not
reported

Literature
review

Sample size not
reported

-Literature search of
PubMed, CINHAHL,
Psych INFO, and
Medline
-Search terms opioid
use disorder,
substance use
disorder, addiction,
postoperative pain,
chronic pain
-Filters English,
human, clinical trial,
or review between
2014-2019

-Physical exam including ROS, pain
assessment, suicide risk, and
withdrawal assessment
-Psychological screening
-Medications for OUD, cognitivebehavioral therapy/counseling
-Nonpharmacological therapies:
CBT, mindfulness meditation,
multimodal interventions, online
pain self-management programs,
exercise, physical rehab,
acupuncture, mind-body practices
-Nonopioid multimodal analgesia
“cornerstone of care”; opioids not
the first line, UDS, a small quantity
of opioids with frequent visits,
Naloxone prescription,
-Psychosocial support

-Individualized treatment
plans with pharmacological
and nonpharmacological
therapies

Umberger
& Gaddis
(2020)

Level VII

Provide an
understanding of
addiction in the
CP patient

Not
reported

Expert
opinion

No sample or setting
reported

No survey or
instrument reported

-Psychiatric and addiction
assessments
-Strong, quality pt/provider
relationship
-Improved outcomes when CP,
addiction, and other comorbidities
dx and tx
-Consideration of adding addiction
training
-Nonpharmacological tx part of tx
plan
-Addiction in the same context as
chronic dx decreases stigma and bias
-Addiction is not cured but sobriety
can be maintained

-Education leads to less bias
-Educate pts and families
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Author
(Year)
Voon et
al. (2017)

Level of
Evidence
Level I

Purpose

Theory

Design

Sample/ Setting

Survey/Instruments

Study Findings

Implications and Limitations

In the opioid
crisis, identify
and tx high-risk
populations

Not
reported

Systemati
c reviews

-1,908 articles
resulted from search
in Medline, Cochran
Library, Psych
INFO, Web of
Science, EMBASE,
and Google Scholar
-18 included in the
study
-Articles between
2000-2016
-Inclusion criteria:
peer-reviewed,
systematic reviews
related to chronic
noncancer pain
(CNCP) and
prescription opioids
(PO) or opioid
misuse
-Low quality-7
-Moderate quality-6
-High quality-5
-4 out of 18 reviews
conducted in Europe

-Data extracted and
synthesized using a
narrative approach
-quality of reviews
assessed using
Assessment of
Multiple Systematic
Reviews (AMSTAR)

-48%-60% of CNCP using PO are
misusing them
-High rates of opioid misuse in pt’s
with dual dx of CNCP and mood
disorders
-Past or present SUD increase risk
for PO misuse
-Evidence supports opioid agonist
(Suboxone) for pt with CNCP and
substance misuse---optimal dosing
for pain relief is a noted research gap

-Need more research around
opioid misuse and CNCP
-Research gap noted in the
role of SUD on the treatment
response outcomes for CNCP
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From: Brad Sisson <cbsisson@coloradoclinic.com>
Sent: Tuesday, June 28, 2022 12:13:09 PM
To: Erin Christiansen <echristiansen@coloradoclinic.com>
Cc: Steffhanie Laurel <slaurel@coloradoclinic.com>
Subject: Re: DNP project site
Great
Glad to help
Brad Sisson MD
970.221.9451 clinic
On Jun 28, 2022, at 12:12 PM, Erin Christiansen <echristiansen@coloradoclinic.com> wrote:
Good afternoon Steffhanie and Dr. Sisson,
I am writing in regards to my DNP project. I would like permission for the Colorado Clinic to be
the main project site for my project. I have drafted a clinical treatment pathway for patients
with chronic pain and opioid use disorder. I would like to send out a short survey and the
pathway to the providers and obtain their feedback. This will be done electronically and will
take less than 10-15 minutes to complete.
In the write up of my project, I will not identify the Colorado Clinic. I will list the project site as
a privately owned integrated pain management clinic located in the Midwest.
Thank you for your continued support in my pursuit of my doctorate.
ERIN CHRISTIANSEN, MSN, FNP-BC
Pain Management Advance Practice Provider
(970) 221-9451
Colorado Clinic
3810 N. Grant Avenue
Loveland, CO 80538
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From: Steffhanie Laurel
Sent: Monday, July 11, 2022 2:10 PM
To: Erin Christiansen
Subject: RE: DNP project site
Hi Erin…of course you may use Colorado Clinic as your project site. Best of luck on this!
Best Regards,
/s/ Steffhanie Laurel
Director of Operations
Office: 719.375.0435, ext. 2173
Fax: 855-856-6479

From: Erin Christiansen <echristiansen@coloradoclinic.com>
Sent: Tuesday, June 28, 2022 12:12 PM
To: Steffhanie Laurel <slaurel@coloradoclinic.com>; Brad Sisson
<cbsisson@coloradoclinic.com>
Subject: DNP project site
Good afternoon Steffhanie and Dr. Sisson,
I am writing in regards to my DNP project. I would like permission for the Colorado Clinic to be
the main project site for my project. I have drafted a clinical treatment pathway for patients
with chronic pain and opioid use disorder. I would like to send out a short survey and the
pathway to the providers and obtain their feedback. This will be done electronically and will
take less than 10-15 minutes to complete.
In the write up of my project, I will not identify the Colorado Clinic. I will list the project site as
a privately owned integrated pain management clinic located in the Midwest.
Thank you for your continued support in my pursuit of my doctorate.
ERIN CHRISTIANSEN, MSN, FNP-BC
Pain Management Advance Practice Provider
(970) 221-9451
Colorado Clinic
3810 N. Grant Avenue
Loveland, CO 80538
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Dear Healthcare Provider,
I am writing today as a candidate for the Doctor of Nursing Practice (DNP) degree at the
University of Northern Colorado School of Nursing. I am confident as a medical provider
specializing in pain medicine your expertise is relevant to my project which includes chronic
pain management in adult patients with opioid use disorder.
I would like to invite you to participate in a project aimed at designing and validating an adult
chronic pain and opioid use disorder clinical pathway designed to provide an integrated and
multidisciplinary chronic pain management treatment plan for those with chronic pain and opioid
use disorder. There is currently no clinical treatment pathway designed to treat patients with
dual diagnoses of chronic pain and opioid use disorder. The purpose of this project is to design
an innovative treatment pathway integrating the current literature with feedback from a panel of
healthcare providers who are experts in pain management. Ideally, the pathway will be piloted
and tested in the clinical setting after the completion of this project.
Should you agree to participate you will be asked to critically review the chronic pain pathway
and to provide feedback via an online survey. The survey is anticipated to be 10 questions with
options for short answer responses focused on the applicability, usefulness, and practicality of
the pain treatment pathway. At the conclusion, your feedback will be aggregated, analyzed, and
used to inform a subsequent draft of the pathway. The total time commitment for participation in
this project is estimated to be 20 minutes. Your responses will be kept anonymous, confidential,
and your participation is completely voluntary.
Please complete and submit the survey as soon as possible but no later than August 31, 2022.
The clinical pathway is attached to this email for easier review and reference when completing
the survey, should you choose to participate. Please feel free to share this email with colleagues
who may be interested in reviewing and commenting on this project.
If you have any questions about this project you may contact me via email at
chri9411@bears.unco.edu or my DNP Project Chair via email at Kathleen.dunemn@unco.edu.
Thank you very much for your time, consideration, and support of this scholarly project. This
project has received approval from the University of Northern Colorado Institutional Board
(IRB).
Sincerely,
Erin Christiansen, DNP Candidate, BSN, MSN, FNP-BC
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Purpose and Procedures: The purpose of this survey is to gather your thoughts, opinions, and
feedback on the validity, usability, feasibility, and accuracy of the attached clinical pathway
designed to improve the health care of patients with dual diagnoses of chronic pain and opioid
use disorder. The clinic pathway guiding chronic pain management of patients with opioid use
disorder is presented and you are asked to review its contents. All responses are completely
confidential. Responses will be utilized to further the development of the clinical pathway’s
validity, usability, feasibility, and accuracy. The de-identified data collected from this survey
will be stored according to UNC’s data security procedures. This DNP research project has
received approval from the UNC Institutional Review Board in the Office of Research and
Sponsored Programs. By completing and submitting this survey, your consent to participate is
implied.
Note: Surveys for this DNP scholarly project will be conducted using Qualtrics Survey Software.
Before you begin, please note the data you provide may be collected and used by Qualtrics’s
parent company (Amazon) per its privacy agreement. You should be aware that these web
services may be able to link your responses to your ID in ways that are not bound by this consent
form and the data confidentiality procedures used in this DNP project study. If you have
concerns you should consult these services directly.

Questions or Concerns: If you have questions about this project, please contact the student
researcher and primary investigator, Erin Christiansen at chri9411@bears.unco.edu or by phone
at 970-290-7467. You may also contact the project Chair, Dr. Kathleen Dunemn, PhD, APRN,
CNM at kathleen.dunemn@unco.edu or 803-409-8391 at any time. If you have any concerns
about your selection or treatment as a research participant, please contact Nicole Morse,
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Research Compliance Manager, University of Northern Colorado at nicole.morse@unco.edu or
970-351-1910.
Voluntary Participation: Please understand that your participation in this project is voluntary.
You may decide not to participate in this project at any time. If you have begun to participate,
you may stop and withdraw at any time. Your decision will be respected and will not result in
loss of benefits to which you are otherwise entitled.

Demographic Information: Please answer the following questions to ensure that you met the
project’s inclusion criteria and so that we may better understand the composition of the expert
panel. All responses will be kept completely confidential and will be aggregated for analysis.

1. What is your current professional title?
a. Doctor of Osteopathy
b. Medical Doctor
c. Nurse Practitioner
d. Physician Assistant
e. Other [free text limit 50 characters]
2. How many years have you been working in your current profession?
a. 0-1
b. 2-4
c. 5-9
d. 10+
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3. Do you have experience in working with the chronic pain and opioid use disorder adult
populations?
e. Yes
f. No
4. What is your age?
g. 18-25y
h. 26-35y
i. 36-45y
j. 46y-55y
k. 56y+
5. Please review the content of the clinical pathway. Is the clinical pathway accurate and
reflective of current literature and standards of practice?
a. Yes
[open text response welcome]
b. No
[open text response welcome]
6. In your expert opinion would you assess the clinical pathway as having a logical basis or
reasonable (i.e., valid)?
f. Yes
[open text response welcome]
g. No
[open text response welcome]
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7. Is the clinical pathway feasible, easily, or conveniently workable?
a. Yes
[open text response welcome]
b. No
[open text response welcome]
8. Would you utilize the clinical pathway in your current practice?
c. Yes
[open text response welcome]
d. No
[open text response welcome]
9. Is there any other important and key information you feel is missing from the proposed
clinical pathway?
[open text response]
10. Do you have any suggestions to make the clinical pathway more applicable to practice?
Is there any other key information, suggestions, or comments you would like to add to the
proposed clinical pathway?
[open text response]
Thank you for reviewing the proposed clinical pathway, providing your feedback, and
completing the survey. Your responses will be analyzed along with those of the other panelists
and incorporated into the clinical pathway.

